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https://doi.org/10.1016/j.cell.2021.03.023SUMMARYGlioblastoma multiforme (GBM) is an aggressive brain tumor for which current immunotherapy approaches
have been unsuccessful. Here, we explore the mechanisms underlying immune evasion in GBM. By serially
transplanting GBM stem cells (GSCs) into immunocompetent hosts, we uncover an acquired capability of
GSCs to escape immune clearance by establishing an enhanced immunosuppressive tumor microenviron-
ment. Mechanistically, this is not elicited via genetic selection of tumor subclones, but through an epigenetic
immunoediting process wherein stable transcriptional and epigenetic changes in GSCs are enforced
following immune attack. These changes launch a myeloid-affiliated transcriptional program, which leads
to increased recruitment of tumor-associated macrophages. Furthermore, we identify similar epigenetic
and transcriptional signatures in human mesenchymal subtype GSCs. We conclude that epigenetic immu-
noediting may drive an acquired immune evasion program in the most aggressive mesenchymal GBM sub-
type by reshaping the tumor immune microenvironment.INTRODUCTION
Glioblastoma multiforme (GBM) is an incurable form of adult
brain cancer with a dismal patient prognosis. Limited therapeutic
options are available for GBMs as they are often detected late,
they are highly infiltrative, and they display significant inter-
and intra-tumoral genetic heterogeneity (Aldape et al., 2019).
Many GBM driver mutations have been identified following
genome-wide sequencing. The PI3K- and mitogen-activated
protein kinase (MAPK)-associated signaling pathways are
frequently co-activated in GBM through activation or amplifica-Cell 184, 1–1
This is an open access article under the CC BY-Ntion of EGFR or PDGFRA and are often accompanied by muta-
tion of the tumor suppressors NF1, TP53, and/or PTEN (Brennan
et al., 2013).
GBMs also display heterogeneity in their transcriptional cir-
cuits and epigenetic landscapes. Threemajor transcriptional sig-
natures of GBM have been reported: proneural (PN), classical
(CL), and mesenchymal (MES) (Verhaak et al., 2010; Wang
et al., 2017). However, individual GBM tumors contain mixtures
of cells with each of these subtype signatures, and the propor-
tion of cells with each subtype can shift upon disease relapse
following therapy (Brennan et al., 2013; Neftel et al., 2019; Patel7, April 29, 2021 ª 2021 The Authors. Published by Elsevier Inc. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(legend on next page)
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Articleet al., 2014; Wang et al., 2017). Single-cell RNA sequencing
(RNA-seq) and lineage tracing studies have indicated that
GBM cells can display plasticity and transit between cell states,
suggesting that the tumor microenvironment (TME), as well as
genetic and neurodevelopmental programs, may influence these
transcriptional signatures (Neftel et al., 2019). GBM subtypes
should not, therefore, be viewed as stable, distinct disease en-
tities; rather, they reflect different proportions of various cell
states that can shift throughout tumor development.
Neftel et al. (2019) have proposed four distinct tumor cell
states in GBM: three of these—neural stem cell-like, oligoden-
drocyte progenitor cell-like, and astrocyte-like— mirror cell
types within a neurodevelopmental differentiation hierarchy.
However, a fourth cell state, termed ‘‘mesenchymal-like,’’ does
not seem to correspond to a specific cell type. Themesenchymal
GBM subtype has the poorest survival rates and displays
increased immune infiltration within the TME, relative to other
subtypes (Wang et al., 2017). This increased immune infiltrate
correlates with loss of NF1; however, this is neither necessary
nor sufficient to explain the emergence of a mesenchymal signa-
ture (Verhaak et al., 2010), suggesting additional processesmust
contribute to the development of an immunosuppressive TME.
Understanding the etiology of the GBM mesenchymal-like cell
state and the origins of its associated transcriptional subtype
will be important for elucidating mechanisms of immune evasion
(Lim et al., 2018).
Mechanisms underpinning the establishment of a pro-tumori-
genic immune microenvironment in GBM remain unclear. To
date, a lack of tractable and immunocompetent models of
GBM have hampered efforts to dissect the relationship between
GBMand the TME and the relative contribution of genetic, epige-
netic, and environmental perturbations in directing tumor cell
states. Here, we address the origins andmechanisms of immune
evasion phenotypes in mesenchymal GBM by engineering a set
of isogenic mouse GBM-initiating cells. Serial transplantation of
transformed cells through syngeneic, immunocompetent hosts
allowed us tomonitor and dissect the progressive transcriptional
and epigenetic changes that occur as GBM cells acquire im-
mune evasion capabilities.
Our findings reveal a mechanism involving epigenetic immu-
noediting, in which exposure to immune attack leads to stable
changes in transcriptional circuits, including critical myeloid-
affiliated transcription factors and other immune-related path-
ways, in GBM cells. This occurs in the absence of clonal geneticFigure 1. Engineered GSCs acquire immune evasion capabilities upon
(A) NSC isolation from BL6 mice and engineering of GBM driver mutations.
(B) Immunoblots showing NF1 and PTEN expression in NP cells versus wild-type
(C) Immunoblot confirming overexpression of EGFRvIII in NPE cells.
(D) Representative stereomicroscope images of GFP+ NPE tumors in NSGmice (w
(E) H&E staining of NPE tumors in NSG (upper panel), scale bar, 50 mm; immunofl
NPE tumors (lower panel), scale bar, 20 mm.
(F) Reverse-phase protein array (RPPA) analysis of common cancer driver pathw
(G) Representative bioluminescent imaging of NPE tumor progression in vivo in B
(H) Representative stereomicroscope images of GFP+ NPE tumors in BL6 hosts
(I) Experimental design for tumor cell derivation and serial transplantation of NPE
(J) Survival curves following orthotopic transplantation of: wild-type NSCs into BL
green curve) into NSG mice; NPE (n = 19, yellow curve), NPE-BL6-TD (n = 27, lig
See also Figure S1.selection and is likely enforced by sustained signaling from re-
cruited tumor associated macrophages (TAMs). These acquired
transcriptional circuits are stabilized by epigenetic changes and,
therefore, persist in tumor cell descendants. We demonstrate
that this leads to remodeling of the TME and the establishment
of a protumorigenic microenvironment.
RESULTS
Engineered GSCs acquire immune evasion capabilities
upon serial transplantation through
immunocompetent hosts
GBM is driven by cells with neural stem cell (NSC) characteristics
(Lathia et al., 2015). Genetically engineered mouse models and
genome analysis of patient samples indicates that endogenous
NSCs can be a cell-of-origin for GBM (Alcantara Llaguno et al.,
2016; Lee et al., 2018). We, therefore, engineered a set of
isogenic GBM stem cells (GSCs) from NSCs isolated from
C57BL/6 J (BL6) mice, by introducing one of five well established
genetic GBM driver mutations: EGFRvIII or PDGFRA overex-
pression or CRISPR/Cas-mediated ablation of Nf1, Pten, or
Trp53 (Figures 1A and S1A–S1G; Table S1; Bressan et al.,
2017; Conti et al., 2005; Robertson et al., 2019). These ‘‘single
hit’’ knockout GSCs expressed typical NSC markers (NESTIN
andSOX2) andmaintained the ability to differentiate into neurons
and astrocytes (Figure S1H).
Next, we generated combinations of mutations to model the
mesenchymal subtype. First, we created double mutant NSCs,
via co-deletion of Nf1 and Pten (‘‘NP’’ cells) (Figures 1A and
1B). These mutations occur together frequently in human
mesenchymal GBM.Orthotopic transplantation of GFP+ NP cells
into immunocompromised (NOD-scid-gamma [NSG]) mice led
to the formation of small, benign growths (Figure S1I). Only
when further engineered with EGFRvIII overexpression—forming
a triple mutant cell line termed ‘‘NPE’’ (Figures 1A and 1C)—did
we observe extremely aggressive tumor growth and infiltration
in vivo (Figure 1D) with the expected hallmarks of GBM (Fig-
ure 1E). Concomitant mutation ofNf1 and Pten alongside EGFR-
vIII overexpression (termed NPE-Multiplex [NPE-Mx]) in an
independent BL6 NSC line confirmed the requirement of this tri-
ple combination for tumor formation (Figures S1J–S1L). We also
generated a tumor-initiating cell line corresponding to the pro-
neural subtype, termed ‘‘PPP,’’ with PDGFRA overexpression
alongside Trp53 and Pten mutations (Figures S1M–S1O). PPPserial transplantation through immunocompetent hosts
BL6 NSCs.
hole brain live imaging; top, GFP; bottom, GFP/bright field [BF] overlay, n = 15).
uorescence of common NSC (GFAP/Nestin) and proliferation (Ki67) markers in
ays in wild-type BL6 NSCs versus mutant cell lines.
L6 recipients. Number of days post-surgery noted above images.
(whole brain live imaging; top, GFP; bottom, GFP/bright field [BF] overlay).
cells in NSG and BL6 mice.
6 mice (n = 4, turquoise curve); NPE (n = 15, orange curve), or NPE-IE (n = 12,
ht purple curve), or NPE-IE (n = 33, dark purple curve) into BL6 mice.
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Figure 2. Whole brain immune population profiling reveals recapitulation of human GBM
(A) Multi-parametric flow cytometry uniform manifold approximation and projection (UMAP) of immune cell populations (CD45+) in whole brains of non-trans-
planted BL6 mice versus those with NPE or NPE-IE tumors; n = 4 brains per condition.
(B) Quantification of macrophage (left) and microglia (right) populations in (A).
(C) Quantification of CD8 T cell (left), CD4 Treg (center), and FOXP3 CD4 T cell populations in (A).
(D) Multi-parametric flow cytometry UMAP of myeloid populations (CD45+/CD11b+) in whole brains of non-transplanted BL6mice versus those with NPE or NPE-
IE tumors; n = 4 per condition.
(legend continued on next page)
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Articletumor models were much less aggressive than their NPE coun-
terparts (Figures S1P and S1Q).
Reverse-phase protein array (RPPA) analysis confirmed the
expected activation of both RTK and PI3K signaling pathways
in mutant NSCs, including elevated ERK, Ras, Raf, mTor, Akt,
and Src expression (Figure 1F). We noted differences between
NPE and PPP cells, with EGFRvIII overexpression stimulating
increased pERK and STAT3 expression in the NPE mesen-
chymal model, consistent with previous reports in human tumors
(Carro et al., 2010). The proneural subtype of GBM is known to
have a reduced immune infiltrate and a less immunosuppressive
TME (Wang et al., 2017). Given this, and the much more aggres-
sive nature of NPE cells and their correspondence to the most
immune evasive mesenchymal GBM subtype, we decided
to focus on the NPE model to explore immune evasion
mechanisms.
We confirmed that NPE cells are tumorigenic in immunocom-
petent, syngeneic BL6 hosts (Figures 1G and 1H), allowing us to
model interactions between GBM cells and the immune TME.
Tumors formed in parallel in immunocompromised NSG mice
served as an important reference control (Figure 1I). Indeed, in
contrast to the 3-week survival observed in all NSG hosts,
NPE tumors arose in BL6 mice at a slower rate than in NSG
mice (25–50 days versus 15–20 days, respectively) (Figure 1J,
yellow curve versus orange curve), and the majority of BL6 hosts
survived long-term, with no detectable tumor (Figures 1G).
These data are consistent with the BL6 host immune system re-
sponding to NPE cells and constraining their tumor formation.
We reasoned that cells with acquired immune evasion capabil-
ities may be enriched by deriving primary GSC cultures from tu-
mors that evade immune surveillance in BL6mice following serial
transplantation of these through fresh hosts.We therefore estab-
lished fresh cultures from the NPE tumors of BL6 mice (termed
NPE-BL6-TD [tumor-derived]) (Figure 1I). NPE-BL6-TD cells
in vitro retained expression of NSC markers and contained no
contaminating CD45+ immune cell populations (Figure S1R).
NPE-BL6-TD cells were transplanted into fresh, secondary BL6
recipients (Figure 1I) and formed tumors with increased fre-
quency (Figures 1J, light purple curve, and S1S). GSC cultures
re-derived from these secondary tumors (herein termed NPE-
IE [immune evasive]) were then transplanted into fresh BL6 hosts
(tertiary recipients) (Figure 1I). BL6 mice transplanted with NPE-
IE cells displayed increased tumor formation with significantly
worse survival than previously transplanted lines (Figures 1J,
dark purple curve, and S1S). However, NPE and NPE-IE cells
showed similar tumorigenicity when transplanted in control
NSG mice, and we detected no proliferative advantage for
NPE-IE cells in vitro or evident genomic instability (Figures 1J,
green curve versus orange curve, S1T, and S1U). Together,
these results indicate that NPE-IE cells have acquired immune
evasion capabilities, which accounts for their increased tumor
formation in BL6 recipients. This is consistent with a form of im-
munoediting (Schreiber et al., 2011), whereby sustained immune(E) Representative fluorescent IHC of macrophage populations (F4/80+, Iba1+
bar, 200 mm.
(F) Quantification of Iba1+ F4/80+ populations in (E) shown as frequency per mm
See also Figure S2.attack leads to the emergence of cells with increased ability to
evade immune surveillance.
Immune evasive NPE-IE tumors possess a highly
immunosuppressive microenvironment
To confirm if the NPE-IE tumors were more aggressive due to an
ability to escape from T cell clearance, we depleted CD8 T cell
populations in BL6 mice with NPE, NPE-BL6-TD, and NPE-IE
tumors (Figure S2A). In all cases, we observed accelerated tu-
mor growth and a progressive increase in tumor penetrance.
This confirms that tumors generated from the NPE line and its
derivatives do not undergo antigen loss, and they remain under
considerable pressure from CD8 T cell-mediated clearance,
from which they are actively escaping.
Next, using flow cytometry, we characterized and compared
immune cell types present in non-tumor bearing brains versus
those harboring NPE or NPE-IE tumors. In tumor-bearing brains,
we observed major changes in the total brain immune cell reper-
toire (Figures 2A–2D, S2B, and S2C), including a significant in-
crease in macrophages and CD8/CD4 T cells, markers of both
M1- andM2-like macrophages, and an apparent decrease in mi-
croglia. Further, we observed lymphoid populations in tumor-
bearing brains display markers of dysfunction, such as PD-1
and TIM3 expression (Figure S2D). Importantly, fluorescent
immunohistochemistry of tumor and adjacent tissue suggested
that the dominating macrophage populations (F4/80+Iba1+) are
localized to the tumor mass and are not generally increased
throughout the brain (Figures 2E, 2F, S2E, and S2F).
We directly isolated the tumor mass to further characterize the
tumor immune microenvironment. Multiparametric flow cytome-
try data revealed increased immune cell infiltration in NPE-IE tu-
mors relative to NPE tumors (Figures 3A, 3B, S3A, and S3B).
Importantly, there was a significant increase in monocytic-
myeloid derived suppressor cells (M-MDSCs) and macrophages
in NPE-IE tumors (Figures 3C and 3D), with tumor-infiltrating
macrophages expressing significantly higher levels of PD-L1
than microglia (Figures 3E and S3C). We did not observe evi-
dence of a phenotypic macrophage switch in NPE-IE tumors
when compared with NPE tumors; rather, macrophages in
each case displayed classical phagocytic and antigen present-
ing phenotypes (i.e., CD86+ and CD11c+, Figure S3D), alongside
the immunosuppressive marker PD-L1 (Figures 3E and S3E).
There were no major changes noted in natural killer (NK) or den-
dritic cell populations (Figures S3F–S3H).
Blockade of CSF-1R signaling diminishes the capacity
for immune evasion in NPE-IE cells
Previous reports have identified the macrophage colony stimu-
lating factor 1 receptor (CSF-1R) as a potentially promising
target for the treatment of gliomas (Pyonteck et al., 2013). To
determine whether the increased macrophages recruited to
NPE-IE tumors support immune evasion, we next depleted
these cells in BL6 mice using a blocking antibody targeting) in NPE or NPE-IE tumors/adjacent tissue; (n = 3–5 per condition), scale
2. One-way ANOVA, n = 3–5 brains from each condition analyzed.
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Figure 3. Immune evasive NPE-IE tumors possess a highly immunosuppressive microenvironment
(A) Fast interpolation-based t-distributed stochastic neighborhood embedding (FIt-SNE) maps of cell populations in NPE and NPE-IE tumors.
(B) Quantification of cell population frequencies in (A) as proportion of total live cell population (n = 4 per condition).
(C) Flt-SNE maps of myeloid (CD11b+) cells in NPE and NPE-IE tumors.
(D) Quantification of macrophage, M-MDSCs, and microglia frequency in (C) as proportion of total live cell population (n = 4 per condition).
(E) PD-L1 median fluorescent intensity (MFI) quantification on microglia and macrophages in NPE and NPE-IE tumors (n = 4 per condition).
(F) Bioluminescent imaging of NPE-IE tumor progression in BL6 in vivo following intraperitoneal (i.p.) injection of aCSF-1R or PBS.
(G) Survival analysis of BL6 mice orthotopically injected with NPE-IE cells and subjected to i.p. injection of aCSF-1R (n = 17) or PBS (n = 11).
(H) Quantification of CD8+/CD4+ T cell population frequencies in NPE and NPE-IE tumors as a proportion of total live cell population in (A) (n = 6 per condition).
(I) Phenotypic marker expression of CD8+/CD4+ T cell subsets from (A) (n = 6 per condition).
For Flt-SNE plots, data were generated from 150,000 live cells randomly sampled from 3 tumors per condition (50,000 live events shown per tumor).
See also Figure S3.
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ArticleCSF-1R. This resulted in increased survival and even clearance
of large, well-established NPE-IE tumors (Figures 3F and
3G). There was no significant impact of this treatment in immu-
nocompromised NSG transplanted controls (Figure S3I). Thus,
tumor-associatedmacrophages play a key role in sustaining the
growth and immune evasive qualities of NPE-IE tumors in
BL6 mice.
Although there was no significant difference in the frequency
of various T cell populations within NPE-IE tumors (Figure 3H),
we did identify an increase in both CD8 and CD4 T cell popula-
tions positive for the markers PD-1 and LAG3 (Figure 3I). This in-
dicates that the NPE-IE TME exhibits an elevated state of T cell
dysfunction and enhanced immunosuppressive functions (Bur-
ugu et al., 2018). As mentioned, macrophages in both tumor
types were highly positive for expression of the PD-1 ligand,
PD-L1 (Figure 3E), and we found microglia were positive for
expression of the LAG3 ligand, MHC-II (Figure 2D), suggesting
the presence of additional immunosuppressive pathways
beyond TAM recruitment. Our analyses highlight the utility of
these GBM models, which reflect the features and immune
repertoire of human mesenchymal GBM. We find that NPE-
derived tumors can progressively escape CD8 T cell clearance
and establish an increasingly myeloid-enriched and pro-tumori-
genic TME, with accompanying T cell exhaustion.
Immune evasive cells undergo significant
transcriptional reconfiguration following immune attack
To uncover the mechanism of acquired immune evasion
observed in NPE-IE cells, we characterized their genome, tran-
scriptome, and epigenome. Importantly, both karyotyping (Fig-
ure S1U) and whole genome sequencing (WGS) of the NPE
and NPE-IE cells revealed no significant genetic disruptions—
either ploidy, structural, or point mutations—when compared
to parental, wild-type NSCs (Figure S4A). This suggests that it
is not clonal evolution or classic genetic immunoediting pro-
cesses that explain the acquired immune evasion properties
observed in NPE-IE tumors. We reasoned that NPE-IE cells
may have acquired other cell-intrinsic and stable changes in
gene expression that support immune evasion.
We performed mRNA-seq analysis on our panel of cells,
including singlemutant lines and those derived fromNSG tumors
(a reference control for in vivo microenvironment exposure,
without immune attack). Strikingly, of the single mutant lines,
Nf1 loss stood out as having a transcriptome closest to the fully
transformed NPE mutants (Figure S4B). Nf1 loss alone revealed
enrichment of several gene signatures relevant to GBM,
including notable activation of angiogenic and cell migration
pathways (Figure S4C; Table S2). This is consistent with
increased angiogenic signatures observed in the mesenchymal
subtype (Verhaak et al., 2010; Wang et al., 2017) and suggests
that loss of Nf1 may ‘‘prime’’ cells for malignant transformation.
Importantly, however, the immune evasive lines (NPE-BL6-TD
and NPE-IE) acquired significantly different transcriptional pat-
terns that were not explained by Nf1 loss alone; these included
many immune-associated genes and Gene Ontology (GO) terms
(Figures 4A–4C). We noted upregulation of several chemokines
in NPE-IE cells (Figures 4D–4G; Table S3), particularly Ccl9,
which has been previously linked to the establishment of pro-tumorigenic microenvironments (Kortlever et al., 2017) and could
explain the increased myeloid cell content of NPE-IE tumors.
Another interesting candidate upregulated in cells derived from
immunocompetent hosts was Irf8 (interferon regulatory factor
8) (Figure 4B). Activation of Irf8 expression was surprising,
because this is a myeloid-specific master transcription factor
that is typically exclusively expressed in hematopoietic cells
(Driggers et al., 1990) and has known roles in myeloid lineage
specification and macrophage differentiation (Holtschke et al.,
1996; Tamura et al., 2000). Irf8 is normally silent in NSCs, thus,
following immune attack, NPE cells can inappropriately ‘‘hijack’’
expression of a myeloid master regulatory transcription factor.
Together, these findings demonstrate that the in vivo immune
attack triggers significant transcriptional changes in NPE cells.
Immune evasion in NPE-IE lines is underpinned by
epigenetic immunoediting
Given that the transcriptional changes induced following in vivo
immune attack are stably retained following ex vivo expansion,
we reasoned that epigenetic changes may have occurred. We
profiled genome-wide DNA methylation patterns using reduced
representation bisulfite sequencing (RRBS). Principal-compo-
nent analysis (PCA) analysis revealed three distinct groups (Fig-
ure 5A), and we identified striking hypomethylation in cells
transplanted in vivo (Figures 5B and S4D). The NPE-BL6-TD
andNPE-IE lines clustered particularly closely byPCA (Figure 5A)
and demonstrated widespread hypomethylation in comparison
to NPE cells (Figure 5C). Consistent with mRNA-seq data, we
foundmany differentially demethylated genes in immune evasive
cells were related to immune processes (Figures 5D and S4E).
One of the most significant differentially methylated regions
occurred within the Irf8 promoter region and gene body, with
methylation progressively erased in the NPE-BL6-TD and NPE-
IE lines, consistent with increased transcriptional activation (Fig-
ures 5D, 5E, and S4F). These changes in DNA methylation
patterns suggest a process of ‘‘epigenetic immunoediting,’’ in
which transcriptional changes imposed by immune attack are
stabilized and selected for in those cells with increased immune
evasive qualities. This would lead to highly immune evasive and
transcriptionally altered descendants. Interestingly, we identified
methylation loss at other well-known immune evasion regula-
tors, including Nt5e (CD73), and Cd274 (PDL1) (Figure S4F), in
line with these genes being primed for reactivation in vivo.
Indeed, we see transcriptional activation of Nt5e in the NPE-IE
tumor cells (Figure S4G), which has been recently identified as
a critical GBM immunotherapy target that is elevated in TAMs
(Goswami et al., 2020).
Irf8 is responsive to interferon gamma and TAMs in NPE
cells in vitro and is important for immune evasion
Irf8 is known to be induced in macrophages via interferon
gamma (IFNg)-induced STAT1 signaling (Contursi et al., 2000).
‘‘Response to IFNg’’ was an enriched GO term in the NPE-IE
lines (Figure 6A), so we postulated that chronic IFNg signals
from the immune TME (Mojic et al., 2017) may stimulate activa-
tion of Irf8 expression in NPE cells. We tested this directly
in vitro by exposing immune-naive NPE cells to IFNg. Irf8 tran-
scription was indeed activated in these cells, and we foundCell 184, 1–17, April 29, 2021 7
Figure 4. Immune evasive cells undergo significant transcriptional reconfiguration following immune attack
(A) PCA (principal component analysis) of mRNA-seq data (top 500 most variable genes) from NPE cells and derivative lines
(B) Heatmap of Z scaled normalized counts for genes specific to NPE-BL6-TD and NPE-IE lines ordered by log2 fold change (NPE-BL6-TD and NPE-IE versus all
others) (top). Z scaled normalized counts of specific genes shown in (B) across all mutants (red trend line indicates mean Z scaled expression) (bottom).
(C) Heatmap of ssGSEA enrichment for select immune associated GO signatures across cell lines (top panel) and ssGSEA enrichment for Verhaak subtypes
(proneural [PN], classical [CL], mesenchymal [MES]) (bottom) (-log10 p values (red/blue), simplicity scores (white/gray), and ssGSEA enrichment (red/yellow/blue)
reported).
(D) Gene set enrichment analysis (GSEA) plot of chemokine-mediated signaling pathway for genes differentially expressed between NPE-IE and NPE-BL6-TD
samples (enrichment score [ES] and false discovery rate [FDR] reported).
(E) Volcano plot of differentially expressed genes between NPE-BL6-TD and NPE-IE. Ccl9 highlighted as gene with highest log2 fold change.
(F) Normalized read counts of selected chemokines (Ccl9, Ccl6, and Ccl2).
(G) Forward phase protein array analysis of selected chemokines (CCL9, CCL6, and CCL2).
See also Figure S4 and Tables S2 and S3.
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Figure 5. Immune evasion in NPE-IE lines is underpinned by epigenetic immunoediting
(A) PCA of RRBS CpG methylation (top 25% most variable CpG sites).
(B) Density heatmap of CpG methylation (%) across lines.
(C) Density scatterplots of CpG methylation (%) (left) and differentially methylated region (DMR) bar plots (right) (red, hypermethylated DMRs; blue, hypo-
methylated DMRs) in NPE-BL6-TD and NPE-IE lines versus NPE (% DMR methylation change reported).
(D) Rank plots of promoter DMRs (±2 kb TSS) displaying hypomethylation in NPE-BL6-TD (top) and NPE-IE (bottom) versus NPE samples (DMRs with >50%
methylation loss, overlapping genes within immune and interferon GO terms are highlighted in blue).
(E) Mean CpG methylation (%) tracks for profiled samples around Irf8 transcriptional start site.
See also Figure S4.
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NPE-BL6-TD or NPE-IE cells following IFNg treatment (Figures
6B, 6C, and S5A). This is consistent with priming for rapid tran-
scriptional activation following DNA methylation loss at the Irf8
locus. Type I IFN signaling (induced by IFNa/b treatment) was
not capable of inducing expression of Irf8 to the same extent
as IFNg in immune-naive NPE cells in vitro (Figure S5B). Further-
more, the JAK/STAT inhibitor, tofacitinib, reversed expression of
IRF8 in NPE cells but not in NPE-IE cells, suggesting a JAK/
STAT-independent mechanism is operating in NPE-IE cells to
sustain high Irf8 expression (Figure 6D). Using an mCherry
knockin reporter line for Irf8 expression, we confirmed that Irf8
transcription can be induced broadly in NPE cells followingIFNg treatment (Figures S5C and S5D). Moreover, profiling of
directly isolated GFP+ NPE-BL6-TD and NPE-NSG-TD tumor
cells confirmed activation of key genes occurs prior to in vitro
expansion (e.g., Irf8, H2-Ab1) (Figures 6E, S5E, and S5F). Expo-
sure of NPE cells to an immunocompetent in vivo environment is,
therefore, sufficient to induce these observed transcriptional
changes.
To determine the immune cell types within the TME of NPE-IE
tumors that might be driving this transcriptional reconfiguration,
we isolated immune cells from NPE tumors and co-cultured
these with parental NPE cells in vitro (Figures 6F and S5E). Strik-
ingly, our data revealed that infiltrating macrophage populations
(F4/80+, CD45hi) can stimulate similar transcriptional changes inCell 184, 1–17, April 29, 2021 9
Figure 6. Irf8 is responsive to IFNg and TAMs in NPE cells in vitro and is important for immune evasion
(A) GSEA of IFNg response signature in NPE-IE cells (enrichment score [ES] and FDR reported).
(B) RT-qPCR analysis of Irf8 expression in NPE, NPE-BL6-TD and NPE-IE cells in vitro ± IFNg treatment.
(C) Representative immunoblot of IRF8 expression in NPE cell panel ± IFNg time series treatment in vitro (n = 3).
(D) Representative immunoblot of IRF8 and pSTAT1 expression in NPE cell panel with IFNg/Tofacitinib treatment in vitro (n = 3).
(E) qRT-PCR analysis of Irf8 expression in NPE cells in vitro versus GFP+ cells derived directly from NPE tumors in NSG/BL6 hosts. Points represent technical
duplicates of cells isolated from individual animals.
(F) Schematic of NPE cells co-culture with immune populations derived from NPE tumors.
(G) RT-qPCR analysis of Irf8 expression in NPE cells co-cultured as in (F) (paired t test).
(H) Representative bioluminescent imaging of NPE-IE/NPE-IE-Irf8KO tumor progression in BL6 in vivo (Irf8KO clone G4 shown).
(I) Survival of BL6mice orthotopically transplanted with NPE-IE cells versus clonally derived NPE-IE-Irf8KO lines (NPE-IE, n = 12; NPE-IE Irf8KO G4, n = 15; NPE-IE
Irf8KO K6, n = 10; NPE-IE Irf8KO E6, n = 6). p values for survival of each Irf8KO line versus parental NPE-IE: **parental versus Irf8KO G4, p = 0.0047; *parental versus
Irf8KO K6, p = 0.0323; parental versus Irf8KO E6, p = 0.0857.
RT-qPCR data representative of at least 3 biological replicates performed in technical duplicates; relative quantification (RQ) to NPE untreated sample.
See also Figure S5.
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NPE-IE cells (Figures 6G and S5G). This suggests that infiltrating
macrophages could be the source of signals in vivo, such as
IFNg, driving this response. Further, although the proneural10 Cell 184, 1–17, April 29, 2021PPP cells did not generate tumors efficiently in vivo or display im-
mune evasion capabilities, we reasoned that PPP cells may still
respond to the NPE tumor-derived immune cell co-culture, as in
patient tumors the proneural subtype can shift to mesenchymal.
Figure 7. Human GSCs display two predominant major transcriptional subtypes, one of which is defined by IFN signaling and hypo-
methylation and is similar to the mesenchymal subtype from Verhaak et al., 2010
(A) Metagene (S1 Non-MESImm and S2 MESImm) enrichment and Verhaak subtype classification (PN/CL/MES, ssGSEA -log10 p values reported) across
human GSCs.
(B) Heatmap of Z-scaled normalized counts for genes specific to metagenemodules (S1 Non-MESImm/S2MESImm). IFN associated genes specific to S2MESImm
module highlighted.
(C) Pathways enriched within S1 Non-MESImm/S2 MESImm signatures (*terms of interest).
(D) Expression of candidate genes of interest (CCL2, IRF1, IRF7, and IRF8) in human Non-MESImm versus MESImm GSCs.
(E) Density heatmap of CpG methylation levels (beta values) in human GSCs.
(legend continued on next page)
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NPE tumors suggested that similar transcriptional programs
can be activated in proneural models (Figure S5H), consistent
with plasticity of subtype signatures reported by Neftel
et al., (2019).
We next generated NPE-IE Irf8 knockout cell lines. These
showed a less aggressive phenotype, and tumors emerged
with similar kinetics to mice transplanted with immune-naive
NPE cells (Figures 6H, 6I, S5I, and S5J). Taken together, our
data suggest that activation of Irf8 in our model is an important
contributor to immune evasion in NPE-IE cells and may occur
via IFNg-mediated activation in vivo.
Human GSCs display two predominant transcriptional
subtypes and mesenchymal GSCs are defined by IFN
signaling
To assess whether our findings have relevance to human dis-
ease, we performed RNA-seq and molecular subtyping of 36
low passage, patient-derived GSC cultures, using non-negative
matrix factorization (NNMF) to identify key transcriptional meta-
gene modules that distinguish them (Gaujoux and Seoighe,
2010; Figures S6A and S6B). By profiling GSCs expanded
in vitro, we can define potential immune-induced gene expres-
sion changes without the confounding contamination of immune
cells within fresh tumor samples. Two distinct subtypes were
identified: S1, which we termed the non-mesenchymal immune
signature (Non-MESImm), and S2, which we termed the mesen-
chymal-immune signature (MESImm) (Figure 7A). Enrichment of
these meta-gene modules were associated with published sig-
natures by Wang et al. (2017), based on whole tumor transcrip-
tomes (Figure 7A, top panel). A distinct transcriptional profile
was associated with the MESImm subtype that included GO
terms associated with IFN signaling as a dominant feature (Fig-
ures 7B and 7C; Table S4).
Notably, we saw upregulation of several interferon regulatory
factor family members in MESImm-enriched GSCs, including
IRF8 and IRF7; however, a more striking association was seen
for IRF1 (Figure 7D). Human IRF1 is also an IFNg-responsive
transcription factor that has been reported to function alongside
hIRF8 in the development of myeloid cells (Langlais et al., 2016).
Furthermore, we also identify increased expression of CCL2 in
theMESImm signature, whichmay account for increased immune
populations observed inmesenchymal GBM (Figures 7B and 7D;
Qian et al., 2011). Finally, we confirmed enrichment of this ME-
SImm signature in our engineered NPE cells, which increased
as the cell lines acquired immune evasion capabilities (i.e.,
NPE-IE cells) (Figure S6C). Thus, related signatures to those un-
covered in our mouse models are also observed in MESImm hu-
manGBMs. Importantly, these transcriptional signatures are sta-
ble and heritable in long term culture, in the absence of IFN
signals; this is consistent with epigenetic events underlying a
stable change to the transcriptome.(F) Empirical cumulative distribution function (ECDF) for DNA methylation levels (
(G) Bar plot of DMRs between MESImm and Non-MESImm GSCs (red, hyperm
reported).
(H) Density scatterplot of CpG methylation (beta values) between MESImm and N
See also Figures S6 and S7 and Table S4.
12 Cell 184, 1–17, April 29, 2021We validated our MESImm and Non-MESImm subtypes by
comparing our findings with an analysis of independent, publicly
available single-cell RNA-seq (scRNA-seq) data (Neftel et al.,
2019). Similarly to human patient-derived GSC cultures, these
GBMcells could be defined along a single axis of variation, sepa-
rating MESImm and Non-MESImm cells. This axis was marked by
expression of well-known mesenchymal genes such as CD44,
CHI3L1, and VIM, as well as IFN-associated genes defined in
the MESImm signature (Figure S6D). MESImm cells were enriched
for IFN GO terms, IFN associated genes, and IRF family mem-
bers, and the MESImm signature was consistent with previously
defined mesenchymal transcriptional subtypes (Figures S6E–
S6G and S7A; Wang et al., 2017, 2019; Neftel et al., 2019).
This confirms that interferon-driven signatures are present within
mesenchymal patient tumors.
Human MESImm GBMs display similar DNA methylation
changes to NPE-IE cells
To assess if human GBMs enriched for the MESImm module may
also have DNA methylation changes reflective of the mouse
models, we profiled DNAmethylation patterns in patient-derived
GSCs and observed a decreased level of DNAmethylation in the
MESImm subtype (Figures 7E–7H). Furthermore, single-sample
gene set enrichment analysis (ssGSEA) of our patient-derived
GSCs demonstrated that low levels of DNA methylation
observed in the MESImm subtype correlated with previously pub-
lished mesenchymal signatures, as well as the signatures re-
ported here, and could be associated with activation of relevant
immune-related pathways such as IFNg response (Figure S7B).
Notably, in the MESImm samples, we identified a loss of methyl-
ation specifically at CpG islands associated with those genes
and pathways identified in our mouse models, including IRF1,
CCL2, and IRF8 (Figures S7C and S7D). These findings are
consistent with human GBM cells having undergone a similar
process of transcriptional reconfiguration and epigenetic
changes to those observed in the mouse models. Human
GBMs may, therefore, also undergo epigenetic immunoediting
to stabilize this immune evasive state, using similar mechanisms
to those identified in the NPE-IE mouse cells.
DISCUSSION
The specific combination of genetic, epigenetic, and microenvi-
ronmental cues that confers the varied transcriptional states
observed in GBM cells remains poorly understood. Here, we
have shown that a key component of the previously reported
‘‘mesenchymal’’ signature is a transcriptional module acquired
in GBM cells following immune attack that is functionally impor-
tant in facilitating immune evasion. Reconfigured transcription
factor expression profiles and altered transcriptional circuits
lead to the creation of an enhanced myeloid-enriched, immuno-
suppressive microenvironment, which is a feature of the mostbeta values) across GSCs (red, MESImm; blue, Non- MESImm).
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DNA methylation changes, and our results suggest a form of
epigenetic immunoediting—rather than sub-clonal genetic
diversification and selection—can support a striking gain in im-
mune evasion capabilities. Similar transcriptional and DNA
methylation changes are observed in human GBM cells of the
mesenchymal subtype, suggesting this process of epigenetic
immunoediting may occur in patients.
To date, there has been a lack of preclinical mouse models to
explore mechanisms of immune evasion in GBM (Robertson
et al., 2019). The set of isogenic cells we report here enables
rapid production of tumors that recapitulate hallmarks of human
GBM, most notably the immune landscape, in syngeneic, immu-
nocompetent mouse models. A range of immune evasion path-
ways that we identified in the mouse NPE models are relevant
to human disease, primarily the recruitment of pro-tumorigenic
myeloid cells, including tumor cell activation of CD73 (Goswami
et al., 2020) and markers of T cell exhaustion such as PD-1 and
LAG3 (Mohme and Neidert, 2020). Using these models, we have
been able to dissect the transcriptional and epigenetic
changes that result from immune attack and identify mecha-
nisms that then underpin acquired immune evasion. This has
not been previously possible using human xenografts, primary
tumor profiling, or existing syngeneic mouse models. NPE-IE
cells are a renewable and easily shared primary cell line. The
GFP-luciferase reporter enables tracking of tumor cells in live
animals and facile recovery of tumor cells. This should be a
useful model for the research community to deeply dissect
GBM immune biology and support translational studies of
immunotherapies.
We observed increased infiltration of macrophages with
various phenotypes, which is consistent with recent reports
that macrophages mount a multifaceted response in human
GBM (Klemm et al., 2020). Enrichment of M-MDSCs was evident
in our NPE-IE model, and this myeloid progenitor population has
been implicated in glioma progression and is known to be highly
immunosuppressive (Mi et al., 2020). Furthermore, we observed
a phenotypic shift in the microglia populations present in tumor
burdened brains, with MHC-II expression indicative of microglial
activation. GBM is regarded as a relatively immunologically
‘‘cold’’ tumor, with its low mutational burden resulting in limited
availability of neoantigens to support T cell recognition and
effective anti-tumor immunity. Consistent with human disease,
the presence of NPE and NPE-IE tumors in mice leads to
increased infiltration of both CD4+ immunosuppressive Treg cells
and CD8+ T cells into the brain, providing a unique opportunity to
explore these populations in GBM. We find that T cell popula-
tions display elevated co-expression of markers associated
with exhaustion (PD-1, LAG3) and regulatory function (FOXP3,
LAG3) in NPE-IE tumors, which is complimented by increased
expression of PD-L1 and MHC-II (PD-1 and LAG3 ligands) on
macrophages andmicroglia, respectively. These inhibitory path-
ways likely contribute to immune escape of NPE-IE tumors and
may represent potential therapeutic targets either alone or in
combination.
Our engineered GSCs were found to upregulate Irf8. Because
Irf8 is normally restricted to myeloid cells, our findings demon-
strate the ability of GSCs to hijack myeloid-related transcrip-tional modules for immune evasion and chemokine expression.
The acquired ability of GSCs to secrete chemokines following
extensive immune attack may explain the increased presence
of immunosuppressive cells in the NPE-IE models as well as
the MESImm GBM subtype, with both CCL2 and CCL9 previously
implicated in the recruitment of inflammatory monocytes (Qian
et al., 2011; Kortlever et al., 2017).
Because the engineered NPE lines remained genetically stable
(we deliberately avoided mutation of Trp53), it is unlikely that ge-
netic events, clonal selection, or classic genetic immunoediting
can explain our observations. Instead, our data indicate the ex-
istence of a process of epigenetic immunoediting, whereby
following exposure to an in vivo environment and subsequently,
immune attack, GSCs undergo site-specific DNA methylation
changes alongside concomitant transcriptional changes that
lead to activation of several immune-related signatures. The
extent of these changes may vary across the tumor population,
with selective pressures then enabling those with increased
chemokine secretion to survive immune clearance following
macrophage recruitment. The resulting reconfigured transcrip-
tional circuits and modules are stabilized by DNA methylation
changes, enhancing immune evasion.
Wang et al. (2017) previously demonstrated the mesenchymal
signatures of bulk tumors are tumor cell intrinsic and not simply a
feature of contaminating immune cells or associated endothelial
cells. However, it remained unclear how this signature is ac-
quired, because, unlike other GBM subtypes, mesenchymal
GBM does not reflect a normal neurodevelopmental state and
is not precisely defined by specific genetic events—although it
clearly correlates with NF1 loss. Our findings do not diminish
the importance of NF1 loss or related pathways in contributing
to the mesenchymal subtype signature. Indeed, our Nf1/
NSCs clearly show profound transcriptional changes and upre-
gulation of angiogenesis related pathways. Such GBM driver
mutations are a prerequisite for tumorigenesis and help establish
the TME. However, we clearly demonstrate using unbiased func-
tional andmechanistic studies that immune attack itself is driving
amajor component of the changes required for effective immune
evasion, and contributing key modules to the mesenchymal
signature. Interestingly, we uncover a potential self-reinforcing
feedback loop, wherein immune attack drives tumor cells to re-
cruit myeloid cells, which in turn expose cells to even further
increased IFNg. This ultimately results in stable epigenetic
changes that are propagated in the expanding tumor population.
These transcriptional changes are a functionally important
component of immune evasion signatures in mesenchymal
GBM cells. Further mechanistic dissection of this relationship,
in particular the signals provided by the macrophages that drive
this phenotype, may provide a framework to support develop-
ment of TAM-targeting GBM therapies.
Therefore, we propose that Nf1 loss is a key mutation that
primes NPE cells and facilitates the acquired transcriptional
and epigenetic changes that occur in response to immune
attack. This is supported by recent findings that Nf1/ neurons
stimulate downstream T cell and microglial activation that is
essential for low-grade glioma growth (Guo et al., 2020). The
specific downstream events of Nf1 loss, and whether these ef-
fects are due to excessive MAPK signaling or other effectorCell 184, 1–17, April 29, 2021 13
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NSCs suggests these cannot tolerate chronic IFNg and will fail to
expand in culture, whereas mutation of Nf1 can overcome this,
suggesting it provides a key step in tolerating the subsequent
transcriptional changes imposed by immune attack and associ-
ated epigenetic reconfigurations.
Based on our data, the specific signals that trigger the
observed transcriptional signatures are likely to include IFN.
IFN signaling has a well-recognized role in orchestrating anti-
tumor responses (Dunn et al., 2006). However, our data support
a model in which prolonged exposure to IFNgmay be subverted
to the benefit of the tumor cells by facilitating the acquisition of a
pro-tumorigenic TME. We show that IFNg can drive similar tran-
scriptional changes in NPE cells in vitro, and many of the genes
enriched in the NPE-IE cells are downstream effectors of this
signaling pathway. However, we cannot rule out that there are
contributions from other cytokines in vivo, such as TNFa (Bhat
et al., 2013).
Our data suggest that recruited TAMs may be a source of a
sustained IFNg signal; however, other immune cells are known
to produce IFNg and may also contribute. Interestingly, two
recent studies have shown that IFNg can diffuse over long-
ranges, indicating that tumor cells may be exposed to IFNg
throughout the TME (Hoekstra et al., 2020; Thibaut et al.,
2020). Furthermore, previous studies have demonstrated the
ability of in vitro IFNg exposure to lead to epigenome changes
at the chromatin level (Benci et al., 2016). It is likely that IFNg
is, therefore, a major inducer of the acquired immune evasive
properties of NPE-IE cells. However, further studies will be
needed to fully define the source, timing, and action of signals
responsible for transcriptional changes imposed in tumor cells
with the MESImm signature.
Overall, our findings suggest the observed gradient, or contin-
uum, of subtype identities in GBM tumors can be explained by
the extent to which the tumor immune microenvironment has
eroded their epigenetic landscape and altered transcription fac-
tor regulatory networks. This may explain the detection of
‘‘hybrid’’ states by Neftel et al. (2019) that might represent
partially edited states. It is also noteworthy that ECM and wound
healing-associated gene sets correlate with the interferon
signaling signatures in our MESImm subtype (data not shown),
which is consistent with recent reports (Richards et al., 2021).
Activation of wound-healing signatures may relate to physiolog-
ically relevant transcriptional changes that occur in regeneration
and repair, such as is seen in reactive astrocytosis. Taken
together, this implies that the activation of wound healing or
injury response programs may accompany the activation of
immune/interferon-related pathways; however, whether these
programs are related or co-dependent in the establishment of
a mesenchymal phenotype remains unclear.
We conclude that transcriptional and epigenetic reconfigura-
tion and the co-opting of myeloid lineage-specific transcription
factors and transcriptional modules is a tumor cell-intrinsic
response that occurs following immune attack in the TME. We
propose this is exploited in GBM to avoid immune detection
and clearance. It will be of great interest to determine if similar
epigenetic immunoediting processes that we have identified
here in GBM also operate in other brain tumors or carcinomas.14 Cell 184, 1–17, April 29, 2021Limitations of study
We acknowledge that WGS of more NPE-IE lines would allow us
to more definitively rule out the effects of point mutations in
driving the immune evasion response reported here. It will also
be interesting to further dissect the contributions of different
components of the TME on the plasticity of GBM cells using
in vivo and in vitro assays. In particular, exploring the relative
contribution of macrophage recruitment, retention, and polariza-
tion, as well as the roles of other immune cell populations,
requires extensive further studies. Although our analysis of the
human signatures is consistent with our conclusions, further
direct testing of the influence of the immune cells or cytokines
on their transcriptional state is necessary. Deeper characteriza-
tion and testing of our proneural (PPP) model will be needed to
determine how specific the pathways we identify here are to
the mesenchymal subtype. Finally, our data strongly indicate a
role for IFNg in mediating the emergence of the mesenchymal-
like signatures reported throughout our study, however, it will
be necessary to confirm the effects of this cytokine and poten-
tially others in vivo and in vitro.STAR+METHODS
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IB: Phospho-EGF Receptor Tyr1068 Cell Signaling Technology Cat#: 3777
IB: Phospho-STAT1 Cell Signaling Technology Cat#: 9167
IB: Rabbit PTEN Cell Signaling Technology Cat#: 9556
IF: Rat CD45 Novus Cat#: NB100-77417SS
IF: F4/80 BioRad Cat#: MCA497GA
IF: GFP Abcam Cat#: ab13970
IF: Iba1 Abcam Cat#: ab178846
IF: GFAP Sigma Aldrich Cat#: G3893
IF: Nestin DSHB Cat#: Rat-401
IF: p53 Cell Signaling Technology Cat#: 2524
IF: Ki-67 ThermoFisher Cat#: MA5-14520
IF: Sox2 Abcam Cat#: ab2492
IF: Tuj1 BioLegend Cat#: 801202
IN VIVO: CD8 (Clone YTS 169.4) 2BScientific/BioXCell Cat#: BE0117
IN VIVO: CSF1R BioXCell Cat#: BP0213
IN VIVO: IgG2b 2BScientific/BioXCell Cat#: BE0090
Biological samples
Glioma Tissue and Derived Cells Glioma Cellular Genetics
Resource, CRUK, UK
http://gcgr.org.uk
Chemicals, peptides, and recombinant proteins
DMEM/HAMS-F12 Sigma Cat#: D8437
Pen/Strep GIBCO Cat#:15140-122
Glucose Sigma Aldrich Cat#: G8644
MEM-NEAA (100X) GIBCO Cat#: 11140-035
BSA Solution GIBCO Cat#:15260-037
Beta Mercaptoethanol GIBCO Cat#: 31350-010
B27 Supplement (50X) LifeTech/GIBCO Cat#: 17504-044
N2 Supplement (100X) LifeTech/GIBCO Cat#: 17502-048
Recombinant Mouse EGF Peprotech Cat#: 315-09
Recombinant Human FGF Peprotech Cat#: 100-18b
Laminin Cultrex Cat#: 3446-005-01
Accutase Sigma Aldrich Cat#: A6964
Glutamine GIBCO Cat#: 25030-021
Mouse Recombinant IFNa R&D Systems Cat#: 10149-IF
Mouse Recombinant IFNb R&D Systems Cat#: 8234-MB
Mouse Recombinant IFNg Peprotech Cat#: 315-05
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Mouse Recombinant BMP4 Peprotech Cat#: 5020-BP
Colcemid GIBCO Cat#: 15210-040
Potassium Chloride Sigma Aldrich Cat#: P3911
Methanol Fisher Scientific Cat#: 13298233
DAPI Thistle Scientific Cat#: 30-45-01
SG Cell Line Transfection Kit Lonza Cat#: V4XC-3032
Blasticidin Invivogen Cat#: ANT-BL-1
Hygromycin B Life Technologies Cat#: 10687010
DMSO Sigma Aldrich Cat#: 276855
dNTPs Thermo Scientific Cat#: R0191
LongAMP Taq Polymerase NEB Cat#: M0323
Paraformaldehyde Powder 95% Sigma Cat#: 158127
Triton X-100 Merck Life Sciences Cat#: X-100
Goat Serum Sigma Aldrich Cat#: G6767
Milk Powder Marvel N/A
Tween 20 Cambridge Bioscience Cat#: TW0020
SuperScript III Invitrogen Cat#: 18080093
Sodium Azide Fisher Scientific Cat#: 12615117
PBS Tablets Sigma Aldrich Cat#: P4417
Ethanol VWR Cat#: 20821-330
FluoroSave Reagent Calbiochem Cat#: 345789
Liberase Roche Cat#: 05401119001
DNase Sigma Aldrich Cat#: 101041590001
Percoll GE Healthcare Cat#: 17-0891-01
RPMI GIBCO Cat#: 11875
Collagenase D Roche Cat#: COLLD-RO
Red Blood Cell Lysis Buffer Abcam Cat#: ab204733
HBSS GIBCO Cat#: 14170120
FBS GIBCO Cat#: 10270-106
Zombie NIR BioLegend Cat#: 423105
TruStain Fc Block BioLegend Cat#: 101319
SuperG Blocking Buffer Grace Bio Labs Cat#: 105100
IRDye 800CW Streptavidin LI-COR Biosciences Cat#: 926-32230
Taqman Universal PCR Master Mix Applied Biosystems Cat#: 4305719
D-Luciferin potassium salt Cambridge Bioscience Cat#: CAY14681
Critical commercial assays
DNeasy Blood and Tissue Kit QIAGEN Cat#: 69506
RNeasy Mini Kit QIAGEN Cat#: 74104
CytoFix/Cytoperm kit BD Cat#: 554714
Deposited data
Raw and analyzed RNA-seq data (mouse) This manuscript GEO: GSE165386
Raw and analyzed RNA-seq data (human) Glioma Cellular Genetics
Resource, CRUK, UK
https://gcgr.org.uk
Raw and analyzed RRBS data (mouse) This manuscript GEO: GSE165389
Raw and analyzed EPIC array data (human) Glioma Cellular Genetics
Resource, CRUK, UK
https://gcgr.org.uk
Raw WGS data (mouse) This manuscript GEO: GSE165390
Raw and analyzed scRNA-seq (human) Neftel et al., 2019 GEO: GSM3828672
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REAGENT or RESOURCE SOURCE IDENTIFIER
Experimental models: cell lines
C57BL/6 J Neural Stem Cells Steven Pollard Lab, Edinburgh, UK N/A
NPE and other BL6 NSC-derived lines This manuscript N/A
GCGR Human Glioma Stem Cells This paper, Glioma Cellular
Genetics Resource, CRUK, UK
N/A
Experimental models: organisms/strains
Mouse: BL6 (C57BL/6 J) Charles River (original source,
colony bred in house)
Cat#: 632C57BL/6J
Mouse: NSG (NOD-scid-gamma) Charles River (original source,
colony bred in house)
Cat#: 614NSG
Oligonucleotides








Primer pairs (see STAR Methods,
Tables S5 and S6)
This manuscript, Sigma N/A
TaqMan Gene expression assays
(see STAR Methods, Table S7)
ThermoFisher N/A
Recombinant DNA
pET28a/Cas9-Cys Addgene Cat#: 53261
PB-CAG-GFP-LUC-Ires-Bsd This manuscript N/A
pU6-(BbsI)_CBh-Cas9-T2A-mCherry Addgene Cat#: 64324
PB-PyCAG-EGFRvIII-Hygro This manuscript N/A
PyCAG-PDGFRalpha-Ires-Bsd This manuscript N/A
pDONR221 Invitrogen Cat#: 12536017
Software and algorithms
GraphPad Prism 9.0 GraphPad Software, Inc https://www.graphpad.com/
FlowJo FlowJo 10 https://www.flowjo.com/
Fiji/ImageJ Open Source https://imagej.net/Fiji
BioRender BioRender https://biorender.com/
TrimGalore (version 0.5.0) Martin, 2011 https://github.com/FelixKrueger/TrimGalore
kallisto (version 0.44.0) Bray et al., 2016 https://pachterlab.github.io/kallisto/
R Package: tximport (version 1.8.0) Soneson et al., 2015 https://bioconductor.org/packages/release/
bioc/html/tximport.html
R Package: DESeq2 (version 1.27.32) Love et al., 2014 http://bioconductor.org/packages/release/
bioc/html/DESeq2.html
R Package: clusterProfiler (version 3.15.4) Yu et al., 2012 https://bioconductor.org/packages/release/
bioc/html/clusterProfiler.html
R Package: ChIPpeakAnno (version 3.22.0) Zhu et al., 2010 https://www.bioconductor.org/packages/
release/bioc/html/ChIPpeakAnno.html
R Package: NMF (version 0.22.0) Gaujoux and Seoighe, 2010 https://cran.r-project.org/web/packages/
NMF/index.html
R Package: ReactomePA (version 1.31.0) Yu and He, 2016 https://www.bioconductor.org/packages/
release/bioc/html/ReactomePA.html
GSEA (version 3.0) Subramanian et al., 2005 https://www.gsea-msigdb.org/gsea/index.jsp
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nudup.py (version 2.3) NuGEN Technologies https://github.com/tecangenomics/nudup
Bismark (version 0.16.3) Krueger and Andrews, 2011 https://www.bioinformatics.babraham.ac.uk/
projects/bismark/
R Package: DSS (version 2.36.0) Park and Wu, 2016 https://bioconductor.org/packages/release/
bioc/html/DSS.html
R Package: minfi (version 1.34.0) Fortin et al., 2014 https://bioconductor.org/packages/release/
bioc/html/minfi.html
R Package: DMRCate (version 2.2.3) Peters et al., 2015 https://bioconductor.org/packages/release/
bioc/html/DMRcate.html
R Package: scran (version 1.16.0) Lun, McCarthy and Marioni, 2016 https://bioconductor.org/packages/release/
bioc/html/scran.html
bcbio-nextgen (version 1.2.3) bcbio https://github.com/bcbio/bcbio-nextgen
Atropos (version 1.1.25) Didion, Martin and Collins, 2017 https://github.com/jdidion/atropos
Bowtie2 (version 2.3.5.1) Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/bowtie2/
index.shtml
samblaster (version 0.1.25) Faust and Hall, 2014 https://github.com/GregoryFaust/samblaster
VarDict (version 1.6) Lai et al., 2016b https://github.com/AstraZeneca-NGS/VarDict
Strelka2 (version 2.9.10) Kim et al., 2018 https://github.com/Illumina/strelka
Mutect2 (gatk version 3.8) Cibulskis et al., 2013 https://gatk.broadinstitute.org/hc/en-us/articles/
360037593851-Mutect2
freebayes (version 1.1.0.46) Garrison and Marth, 2012 https://github.com/freebayes/freebayes
HaplotypeCaller (gatk version 3.8) DePristo et al., 2011 https://gatk.broadinstitute.org/hc/en-us/articles/
360037225632-HaplotypeCaller
Manta (version 1.6.0) Chen et al., 2016 https://github.com/Illumina/manta
CNVkit (version 0.9.6) Talevich et al., 2016 https://cnvkit.readthedocs.io/en/stable/














Team BC, 2016 http://bioconductor.org/packages/release/data/
annotation/html/BSgenome.Mmusculus.UCSC.
mm10.masked.html
IGV (version 2.8.2) Thorvaldsdóttir et al., 2013 http://software.broadinstitute.org/software/igv/
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Lead contact
Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Steven Pollard (steven.
pollard@ed.ac.uk)
Materials availability
All reagents generated in this study (including cell lines and plasmids) are available on request from S.M.P.e5 Cell 184, 1–17.e1–e13, April 29, 2021
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ArticleData and code availability
The accession numbers for the mouse mRNA-seq, RRBS, and WGS datasets reported in this paper are available to download from
the Gene Expression Omnibus (GEO) with the following accession codes: GSE165386, GSE165389 and GSE165390. Human RNA-
seq, and EPIC array datasets will be made available for download at http://gcgr.org.uk. Additional code is available upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice and in vivo procedures
All treatments and procedures on mice were performed in accordance with protocols approved by Home Office UK guidelines in a
designated facility under a project license to S.M.P., (PC0395462) at the University of Edinburgh. Mice were maintained on a regular
diet in a pathogen-free facility on a 12-hr light/dark cycle with unlimited access to food and water. Intracranial transplantation of
GSCs was performed using a stereotaxic frame to inject 200,000 cells resuspended in 2 ml of NSC media into 6- to 8-week-old
male NOD/SCID/GAMMA (NSG) or C57BL/6 SCRM (BL6) mouse striatum, following administration of isoflourane general anesthesia
and Rimadyl analgesic. Coordinates were 0.6mm anterior and 1.5mm lateral to the Bregma and 2.4 mm deep. Cell preparation and
procedures were done as previously described in Pollard et al. (2009). Bioluminescent imaging was performed 20 minutes after
D-Luciferin (50mg/kg) subcutaneous injection, using the IVIS Lumina LT Series III instrument (Perkin Elmer). For all antibody blocking
experiments, animals were randomly assigned to test and control groups. Blocking antibodies for CD8, CSF1R and IgG2b were
administered by intraperitoneal (IP) injection at doses and frequencies described in the method details.
Cell culture
General cell culture
Mouse and human cells were cultured in serum-free basal medium supplemented with N2 and B27 (Life Technologies), laminin
(Cultrex, 2 mg/ml) and growth factors EGF and FGF2 (Peprotech, 10 ng/ml). Cells were maintained as previously described in Pollard
et al. (2009).
NSC differentiation to astrocytes
Cells were seeded 43 103 cells/ cm2 in NS culturemedia without EGF or FGF2 andwith BMP4 (10 ng/ml). For neuronal differentiation
we seeded cells at 8 3 103 cells/cm2 or 4 3 103 cells/cm2 for the BL6-NP and BL6-NPE in NS basal media without growth factors.
Media was replenished every 3-4 days. Immunostaining for differentiation markers was carried out on day 3 for astrocytes, and day
10 for neurons, post-differentiation initiation.
Co-culture of NPE cells with tumor derived immune cells
3x104 NPE cells were seeded in NSC culture media in a 12-well plate at least 6 hours prior to introduction of immune cells to allow
attachment. F4/80 + and CD3+ immune cells were isolated from tumors and collected by flow (detailed below). F4/80 + cells were
resuspended in ‘minimal macrophage media’ (DMEM high glucose (GIBCO), 10% FBS (GIBCO), 1% pen/strep (GIBCO)) and CD3
cells were resuspended in ‘minimal T cell media’ (complete RPMI 1640 medium (GIBCO) containing 1% pen/strep (GIBCO),
50 mM b-mercaptoethanol (GIBCO), and 1% L-glutamine (GIBCO)) before being seeded in a 3.0 mm pore polycarbonate membrane
transwell insert (SLS, #3402) containing the appropriate medium. Co-culture experiments were carried out overnight (16 – 20 hours).
Cell growth analysis
NPE andNPE-IE cells were seeded in NSC culturemedia in a 24-well plate and growth curveswere determined using Incucyte (Essen
Bioscience) live cell imaging system.
METHOD DETAILS
Design and construction of CRISPR sgRNAs and PiggyBac plasmids
For gene knockouts, two gRNAs were designed to remove or generate indels, these were introduced to the most disease relevant
gene regions in the case of GBM drivers. CRISPR sgRNAs were designed using the Optimized CRISPR Design tool (https://zlab.bio/
guide-design-resources). Sequences are provided in Table S1. For construction of sgRNA-encoding plasmids, single-stranded
oligonucleodies (IDT) containing the guide sequence of the sgRNAs were annealed, phosphorylated and ligated into BsaI site of
U6-BsaI-sgRNA backbone (kindly provided by S. Gerety, Sanger Institute) or U6-BbsI-CBh-Cas9-T2A-mCherry backbone (this
was a gift from Ralf Kuehn, Addgene plasmid # 64324) (Chu et al., 2015).
PiggyBac expression vectors were constructed via Gateway cloning apart from the EGFRvIII construct. The LUC-2A-GFP was
PCR amplified from existing plasmids (gift from M. Pule, UCL). Human PDGFRa was amplified from cDNA of the G144 cell line
(Pollard et al., 2009), PCR products were cloned into Gateway pDONRTM221 using BP cloning. The cassettes were then delivered
into the intermediate targeting vectors via Gateway LR cloning. Plasmids were sequence verified. EGFRvIII was amplified from ex-
isting plasmids (gift from A. Medvinsky lab) incorporating BrsGI restriction sites to clone into a PB-CAG-Ires-Hygro (gift from Keisuke
Kaji). Primers used for construction are provided in Table S5.Cell 184, 1–17.e1–e13, April 29, 2021 e6
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pET28a/Cas9-Cys was a gift from Hyongbum Kim (Ramakrishna et al., 2014). BL21(DE3) cells (New England Biolabs, C2527) were
transformed with the plasmid pET28a/Cas9-Cys (Addgene, Cambridge, USA, plasmid #53261) using standard protocols. Cas9 pro-
tein expression was induced with 0.5 mM IPTG (Isopropyl b-D-1-thiogalactopyranoside) (Fisher, 10715114) and bacterial cells were
incubated overnight at 20C. Bacterial pellets were resuspended in 20mL of lysis buffer (20mMTris-HCl pH 8.0, 500mMNaCl, 1mM
TCEP, 5 mM imidazole pH 8.0), sonicated and loaded on a HisTrap HP 5mL column (GE, 17-5248-01). Cas9 protein was collected in
elution buffer (20 mM Tris-HCl pH 8.0, 250 mM NaCl, 10% glycerol, 1 mM TCEP, 250 mM imidazole pH 8.0). Fractions containing
Cas9 protein were pooled and loaded into a HiPrep 26/10 Desalting Column (GE, 28-4026-52) to equilibrate in Cas9 buffer
(20 mM HEPES-KOH pH 7.5, 150 mM KCl, 1 mM TCEP). Purified Cas9 protein was further concentrated using Vivaspin columns
(Vivaspin20, VS2021) as per the user-guide instructions.
Cell line derivation
Mouse NS cell lines were derived from adult C57BL/6 SCRM subventricular zone as previously described (Conti et al., 2005; Sun
et al., 2008). To obtain tumor cell lines, tumors were dissected from mouse brains and a piece of tumor was transferred into a
35 cm2 well plate with 2 mL of accutase. Tissue was minced into small pieces with scalpels and incubated 30 min at 37C. The ac-
cutase with the tissue was transferred into a falcon before adding 6 mL of serum-free basal medium. Tissue was dissociated with a
glass pipette very gently several times. After centrifugation for 5 min at 500 rcf., the cell pellet was resuspended in complete media
and plated in a T25 flask. Cell debris was removed the following day and fresh media was added. Human brain tumor samples were
dissociated for cell culture as described by Pollard et al. (2009). Briefly, tumor samples were dissociated into single cells using phys-
ical dissociation and accutase incubation for 15 – 20 minutes at 37C, followed by the addition of serum-free basal medium and
centrifugation for 5min at 500 rcf. The cell pellet was resuspended in complete media and plated in a laminin coated flask. Cell debris
was removed the following day and fresh media was added.
Cell transfection
NS cells were transfected using theDN 100 programof a 4D nucleofection system (Lonza). 1.53 106 cells were resuspended in 100 ml
of SG transfection solution (Lonza) containing a maximum of 3 mg DNA. For CRISPR targeting, ratios of gRNAS and Cas9 were 1:1:2.
For transgene overexpression, piggyBac transposase pBase and PB vectors were used in a 1:1 ratio. For multiplex experiments, ra-
tios were equal and the amount of DNA used was 5 mg. Media was changed 6 hours after transfection. Cells were incubated for 48
hours post-transfection prior to FACS sorting.
Drug selection and clonal expansion
Cells with stable integration of the PiggyBac plasmids were selected for 5-7 days using 5 mg/ml blasticidin or 100 mg/ml hygromycin.
For individual TSG knockout experiments, GFP positive cells were enriched by FACS single cell sorting into 96-well plates and
collected in tubes (bulk population). The Irf8 clonal knockout lines were established using the iotaSciences isoCell system. Clones
were expanded after 10-15 days post single cell disposition and transferred into 2 3 96-well replica plates and expanded for cell
banking and gDNA extraction. For NPE-Multiplex experiments, GFP and mCherry double positive cells were sorted and collected
in tubes. These cells were expanded and maintained for 5 days with hygromycin and 6 days with blasticidin and transplanted in
mice without picking colonies. After tumor formation, a cell line was derived, NPE-Mx-TD, and individual colonies were picked
into 2 3 24-well replica plates and expanded for cell banking and gDNA extraction.
Genotyping of knockout clones
Genomic DNA from individual clones was isolated from 24-well plates using DNeasy Blood & Tissue Kit (QIAGEN). 100-150 ng DNA
was used in a 25 mL PCR reaction. PCR reactions comprised 0.3 mL DMSO (100% v/v, Sigma), 1 mL dNTPs (10 mM, Thermo Fisher
Scientific), 5 mL LongAMP buffer (5x NEB), 1 mL LongAMP Taq (NEB), and 1 mL of each primer (at 10 mM concentration). Primer se-
quences are provided in Table S6. Genotyping primers flanking the targeting site of Cas9 were used to identify potential indels and
directly assessed by Sanger sequencing traces from the resulting PCR products.
Immunocytochemistry
Cells were fixed in 4% PFA for 10 min and then blocked in 0.2% Triton X-100 and 3% Goat Serum. Cells were incubated in primary
antibodies overnight at 4C followed by incubation with appropriate secondary antibodies at room temperature for 1 hour. DNA was
stained with a final incubation of cells in 4’,6-diamidino-2-phenylindole (DAPI). The specific dilution of primary antibodies used are as
follows: mouse Nestin (1:10; DSHB, Rat-401), rabbit Sox2 (1:200; abcam ab2494), mouse GFAP (1:200; Sigma G3893), rabbit Ki-67
(1:200; Thermo Fisher MA5-14520), Tuj1 (1:1000; Biolegend, 801202), mouse p53 (1:500; Cell Signaling Technology 2524).
Immunoblotting
Immunoblotting was performed using standard protocols. Antibodies were diluted in blocking solution (5%milk powder in TBS-T or
3% BSA/1% PVP in TBS-T). Protein detection was performed using peroxidase-coupled secondary antibodies (Invitrogen) and
application of homemade ECL before protein detection by exposure to X-ray films or imaging using the ChemiDock system (BioRad).e7 Cell 184, 1–17.e1–e13, April 29, 2021
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EGF Receptor Tyr1068 (1:1000; CST 3777), rabbit PDGFRa (1:1000; CST 3174), mouse GAPDH (1:50000; Ambion, AM4300), mouse
IRF8 (1:500; eBiosciences 14-7888-82), ACTIN (1:1000; Santa Cruz sc-1616), rabbit pSTAT1 (1:1000, CST 9167).
RT-qPCR
RT-qPCR was performed using standard protocols. RNA was isolated and gDNA eliminated using the RNeasy Mini Kit (QIAGEN,
74104). cDNAwas synthesized using SuperScript III (Invitrogen) and RT-qPCRwas performed using the QuantStudio 7 Flex (Applied
Biosystems) instrument. Each sample/gene combination was run in duplicate or triplicate. TaqMan assays used are provided in
Table S7.
RPPA analysis
Cell lysates were prepared and analyzed as previously described (Teo et al., 2018). Briefly, mediumwas removed from the plates and
cells were rinsed twice with PBS. Cells were lysed on ice for 20 minutes with occasional shaking every 5 minutes. Cell lysates were
collected with a scraper and clarified by centrifugation at 18,000 rcf. for 10 min at 4C. Clarified supernatants in biological triplicate
were adjusted to 2mg/mL concentration and printed onto nitrocellulose-coated slides (Grace Bio-Labs) in a dilution series (four serial
2-fold dilutions) in technical triplicate using an Aushon 2470 arrayer (Aushon Biosystems). Slides were blocked, probedwith validated
primary antibodies and detected with DyLight 800-conjugated secondary antibodies (New England BioLabs). Slides were read using
an InnoScan 710-IR scanner (Innopsys) and quantified using Mapix (Innopsys). Relative fluorescence intensities were normalized to
respective FastGreen-stained spots (total protein), and data were computationally analyzed as previously described (Byron, 2017;
Teo et al., 2018).
In vivo antibody administration
Animals were randomly assigned to test and control groups for all antibody blocking experiments. For CD8 T Cell Blockade, mono-
clonal anti-CD8a (Clone YTS 169.4, Cat # BE0117) and anti-IgG2b (Clone LTF-2 Cat # BE0090) antibodies were purchased from
2BScientific (BioXCell) and 20 mg of ɑCD8/IgG2b resuspended in 200 ml of PBS was administered via IP injection on alternate
days, three times per week (Monday, Wednesday, Friday) for three weeks, beginning 3 days post orthotopic transplantation of tumor
cells, to ensure continuous CD8+ T cell depletion. Anti-mouse CSF1R (CD115) was a kind gift from Sergio Quezada (BioXCell Cat #
BP0213). Mice received three doses of 200 mg of anti-CSF1R resuspended in 200 ml of PBS on alternate days, beginning 5 days post-
orthotopic transplantation of tumor cells.
Mouse Brain Fixation, Histopathology and Immunohistochemistry
Brains were fixed in 4% PFA overnight at 4C, then rinsed several times with PBS and stored in PBS +0.05% Sodium Azide. For
Histopathology procedures, brains were transferred into 70% Ethanol media and then embedded in paraffin for processing.
10 mm coronal slices were prepared forhematoxylin and eosin (H&E) staining. For immunohistochemistry of fixed brain tissue,
20 mm vibratome slices were transferred into a 24-well plate. Slices were incubated at room temperature for 30 min in blocking
solution (0.2% Triton X-100 and 3% Goat Serum). Primary antibodies were incubated overnight at 4C as follows: nestin (1:10;
DSHB, Rat-401), chicken GFAP (1:100, BioLegend 829401), rabbit Ki-67 (1:100 Thermo Fisher MA5-14520), GFP (1:300 Abcam
13970). After three washes with PBS, slices were incubated with appropriate Alexa Fluor secondary antibodies (1:1000, Life technol-
ogies) and DAPI (1:2000, Sigma D9542) for 2 hours. Slices were washed three times and were mounted on a slide with FluoroSaveTM
Reagent (345789, Calbiochem). Slices were examined with a confocal microscope (Leica TCS SP8).
Multiplex Immunofluorescence
Staining of deparaffinized 5 mm FFPE sections was performed on automated tissue staining system (Bond-Rx, Leica Microsystems,
CA) in the SURF facility at the University of Edinburgh. Primary antibodies; GFP (ab13970, Abcam Cambridge, MA, dilution 1:200);
F4/80 (MCA497GA, BioRad, Hercules, CA, dilution 1:100); CD45 (NB100-77417SS, Novus, Manchester, UK, dilution, 1:100); Iba1
(ab178846, Abcam, dilution 1:250) were used to detect tumor cells and macrophages. Cells were labeled by using a tyramide signal
amplification kit (Opal 7-color automation kit, NEL797001KT, Akoya BioSci. Menlo Park, CA). Opal 520 (1:150 dilution), Opal 570
(1:300, dilution), Opal 620 (1:150, dilution), Opal 650 (1:300 dilution), reactive fluorophores were used. Slides were counter stained
with DAPI (Sigma-Aldrich, St. Louis, Missouri) and mounted by Prolong Diamond Antifade Mountant (P36965, Thermofisher Sci.,
Waltham, MA). Whole slide brain sections were imaged using the Vectra 3.0 multispectal imaging system (Perkin Elmer) at 20X
magnification.
Image quantification
Images are analyzed in Inform Image analysis software (Version 2.9.4). To spectrally unmix emission spectra of each fluorophore, a
spectral library and spectral unmixing algorithm was created using by using autofluorescent and single Opal dye-stained images.
Background area were segmented from the tissue and removed from the analysis. The tumor regions was identified by using
H&E staining and by staining GFP staining and at least 5 randomly selected ROI regions inside the tumor areawas analyzed per tissue
(20x object lens). Images were processed for nuclear detection (DAPI+ nuclear objects) and cytoplasm detection (2-pixel wide fromCell 184, 1–17.e1–e13, April 29, 2021 e8
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and CD45 markers. At the end of batch processing, the quality of phenotype identification was checked by using processed and
component RGB images. Incorrectly classified images and damaged tissues were removed from the analysis. The total number
of Iba+ and Iba-1 F4/80+ positive cells per mm2 of tissue and and total cells was calculated from the sum of the total images
used per tissue.
Preparation of brain cell suspension for flow cytometry
For whole brain analysis, brains were dissected from mice and mechanically disaggregated using scissors, followed by enzymatic
digestion using liberase (Roche Cat# 05401119001) and DNase (Sigma, Cat: 101041590001). Following enzymatic digestion cells
suspension underwent Percoll (GE Healthcare, ref 17-0891-01) gradient separation to obtain cell suspensions enriched on hemato-
poietic cells. Cell suspensions were incubated 10 minutes with a blocking mixture of mouse, rat and calf serum containing anti-
CD16/32 blocking antibodies (Clone 2.4G2, Bioxcell, Cat: BE0307). Cells were washed with PBS and incubated with a mixture of
flow cytometry monoclonal antibodies per 20 minutes. In order to detect intracellular epitopes cells were fixed and permeabilized
using the BD CytoFix/Cytoperm kit (BD, Cat: 554714) following the manufacturer protocol. Cells were resuspended in PBS and ac-
quired using the FACSymphony. Flow cytometry data was compensated and down sampled to 5000 events using FlowJo. Data from
down-sampled FCS fileswas then clustered usingCytofkit and FlowSom restricted to 20 clusters. Clusters were then visualized using
Uniform Manifold Approximation and Projection (UMAP). All data was analyzed using R version 3.6.2. Antibodies for flow cytometry
were purchased from Biolegend, BD and ThermoFisher Scientific (eBioscience): CD103-UV395 (Clone M290), CD24-BUV496 (Clone
M1/69), Ly6G-BUV563 (Clone IA8), CD11b-BUV661 (Clone M1/70), CD19-BUV737 (Clone 1D3), CD3-BUV737 (Clone 7A2), CD45-
BUV805 (Clone HI30), CD68-BV421 (Clone FA-11), GITRL-BV510 (Clone MIH44), Ly6C (Clone AL-21), CD206-BV650 (Clone
C068C2), MHCII-BV711 (Clone M5-114-15-2), CD11C-BV786 (Clone N418), CD86-FITC (Clone GL1), 41BBL-BB700 (Clone
TKS-1), ICOSL-PE (HK5.3), PDL1-PECF590 (Clone 10F.9G2), OX40L-PeCy7 (Clone RM134L), SIRPa-APC (Clone P84), F4/80-
AF700 (Clone BM8).
For analysis of intra-tumoral immune cell populations, GFP + tumors were dissected from brains and placed in 1 mL RPMI in a
60mm cell culture dish andmechanically dissociated using a sterile scalpel. 2 mL of DMEM supplemented with 2 mg/ml collagenase
D and 10 mg/mLDNase 1was added to the tumor samplewhichwas further dissociated by pipetting before transfer to a 50mL Falcon
tube and incubation at 37C, with shaking at 200 rpm for 30 min. Following enzymatic digestion, 10 mL of PBS was added to the
tumor cell suspension before centrifugation. All centrifugation steps were carried out at 500 rcf. for 5 min at 4C unless otherwise
stated. The supernatant was discarded, and pelleted tumor cells were resuspended in 10 mL of cold PBS and passed through a
cell strainer into a fresh 50 mL Falcon tube, with a further 5 mL cold PBS used to encourage as many remaining cells as possible
to pass through the strainer. Cells were then centrifuged and resuspended in 5 mL of 1X Red Blood Cell Lysis Buffer, incubated
at room temperature for 5 min and pelleted again. The pellet was then resuspended in 10 mL MACs Buffer (1X HBSS + 2% FBS)
and repelleted before decanting MACs Buffer.
To remove myelin, cells were resuspended in remaining residual MACs Buffer and 20 ml of myelin magnetic beads were added to
the cell suspension before a 15min incubation at 4C. A further 5mL ofMACs Buffer was added to the cells before centrifugation and
resuspension in 1 mL of MACs Buffer before transfer to a 15 mL Falcon tube and myelin removal using a MACs machine. Following
this, cells were washed with 5 mL PBS, centrifuged and resuspended in a final volume of 200 ml before transfer of each sample to an
individual well of a 96-well plate. For controls (unstained/viability only), two 20 ml aliquots were removed from each tumor cell sample
and placed in independent wells. The plates were sealed (to prevent cross-contamination) and centrifuged. With exception of the
sample to be used as an unstained control, cell pellets were resuspended in 100 ml of a 1:1000 dilution of Zombie NIR in PBS as
a viability stain (unstained sample resuspended in PBS only) and incubated for 20 min at 4C. Plates were again sealed and centri-
fuged followed by two washes of samples in FACS buffer. Pelleted samples were then blocked (50 ml of 1:200 CD16/32 in FACS
buffer) at 4C for 15 min in the dark. Cells were then stained by adding 50 ml of primary antibody mix to the pre-existing Fc block
solution and incubated for 30 min at 4C in the dark before pelleting and washing in twice in FACS buffer. Samples being stained
for myeloid cell populations were then resuspended in FACS buffer and transferred to FACS tubes for analysis. Samples being
stained for T cell population markers were permeabilized overnight in fixation/permeabilization buffer at 4C and washed twice
the following morning in 1X permeabilization buffer before incubation in 100 ml of anti-FOXP3 for 30 min at 4C in the dark. Finally,
these samples were pelleted, washed twice in FACS buffer and resuspended in FACS buffer and transferred to FACS tubes for anal-
ysis. To generate tSNE maps, Flow cytometry data was randomly down sampled to 50,000 events per tumor for three independent
tumors and the resulting data concatenated into a single dataset using FlowJo. Data from the resulting fcs file was then clustered
using the tSNE plugin in FlowJo with the following settings: Auto(opt-SNE), Iterations: 1000, KNN algorithm: Exact (vantage point
tree), gradient algorithm: Flt-SNE. To identify clusters on the tSNE map, concatenated data was subject to conventional gating as
detailed in Figure S3 and applied to the tSNE map using FlowJo layout editor. All data was analyzed using FlowJo version 10 and
R version 4.0.2.
Antibodies for flow cytometry were purchased fromBiolegend, BD and ThermoFisher Scientific (eBioscience). CD45-AF700 (Clone
30-F11). For the T cell Panel: CD3-BV711 (Clone 17A2), CD8-BUV737 (Clone 53-67), CD4-BV510 (CloneGK1.5), TIM3-PE/Dazzle 594
(Clone B8.2C12), CD62L-BUV395 (Clone MEL-14), CD44-BV650 (Clone 1MF), ST2-APC (Clone RMST2-2), gdTCR-PerCP/Cy5.5
(CloneGL3), FOXP3-eFlour 450 (CloneFJK.16 s), LAG3-PE-Cyanine7 (Clone eBioC9B7W), PD1-BV605 (Clone 29F.1A12),e9 Cell 184, 1–17.e1–e13, April 29, 2021
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1A8), CD31-BV605 (Clone 390), PDL1-BV711 (Clone 10F.9G2), Ly6C-PerCP/Cy5.5 (Clone HK1.4), MMR-PE (Clone C068C2),
CD11c-PE/Dazzele (Clone N418), CD86-PE/Cy7 (Clone GL-1), PDL2-APC (Clone TY25), CD140a-BV650 (Clone APA5).
To isolate immune cells from tumors for co-culture experiments, GFP + tumors were dissected from brains, placed in bijou tube
with 1mL accutase andmechanically dissociatedwith a sterile blade, pipetting and disruption with the IKAUltra TurraxTMTubeDrive
followed by incubation at 37C for 30min. Next, 6ml of wash media was added to the tumor cell suspension before centrifugation (all
centrifugation steps were carried out at 500 rcf. for 5 min at 4C unless otherwise stated), the supernatant was discarded, and cells
were incubated for 10 minutes at room temperature in RBC lysis buffer (abcam). After centrifugation, the tumor cell suspension was
washed once with ice cold PBS + 0.1% BSA and then filtered through a 70 mm cell strainer (Falcon). Tumor suspension was
resuspended in cold PBS + 0.1% BSA and Fc block was added at a concentration of 1:100 for 5 minutes at room temperature.
The suspension was washed once, before resuspension in 100 mL PBS + 0.1% BSA and suitable antibodies for staining and
incubated for 30 minutes, at 4C in the dark. Tumor suspension was then washed twice and resuspended in FACS buffer for sorting.
Antibodies used were: CD45 (1:200, Biolegend), F4/80 (1:100, eBioscience) and CD3 (1:200, Biolegend).
Forward-Phase Protein Arrays (FPPA)
Media was conditioned by cells for 48 hours. Antibody microarrays were printed in-house using an Aushon BioSystems’ 2470 array
printing platform. Microarrays were blocked for 1 hour with SuperGTM Blocking Buffer (Grace Bio Labs) at room temperature on a
rocker. Media from samples were centrifuged at 1000 rcf. for 5 minutes at 4C. Supernatants were added to microarrays for 12 hours
at 4C. Microarrays were washed three times for 5 minutes in TBS-T and blocked for 10 minutes with SuperGTM Blocking Buffer at
room temperature on an orbital shaker, then washed again three times for 5 minutes in TBS-T. Detection antibodies (1:500 antibody
diluted in 5%BSA/PBST, 1%SuperGTMBlocking Buffer) mixturesweremade in plates and 2 mL of each antibodywas applied to each
well of themicroarrays. Microarrays were clamped and 50 mL of each antibody was added to corresponding microarray wells. Micro-
arrays were incubated for 1 hour on a flat surface. Clamps were removed and microarrays were washed three times for 5 minutes in
TBS-T. Microarrays were then blocked for 10 minutes with SuperGTM Blocking Buffer at room temperature on a rocker and again
washed three times for 5 minutes in PBS-T. 3 mL of IRDye 800CW Streptavidin (LI-COR Biosciences) diluted 1 in 5000 in PBST
supplemented with 5% BSA, 1% SuperGTM Blocking Buffer. Microarrays were covered and incubated on a rocker at room temper-
ature for 45 minutes then washed for 5 minutes, three times in PBS-T followed by three 5 min PBS washes and then washed with
distilled water. Microarrays were dried then scanned on the InnoScan 710 high resolution Microarray scanner (Innopsys Life
Sciences). Data was normalized for protein concentration and background fluorescence in Microsoft Excel. Graphs were calculated
using Prism (Graphpad).
RNA-seq sample preparation
All samples were run in triplicate. RNA was extracted from cells using the QIAGEN RNeasy kit.
For mouse samples, sample concentration and quality was assessed using the Aligent Tapestation and Nanodrop, only samples
with a RIN value of 9.6 or above were used. Library prep and mRNA sequencing of mouse samples was performed by University of
Edinburgh Clinical Research Facility Genetics Core. Further quality control was performed by the facility using the Qubit 2.0 Fluorom-
eter and the Qubit RNA BR assay. Library prep was performed with 500ng of starting material using the Illumina TruSeq Stranded
mRNASample Preparation kit. Briefly, poly-A containingmRNAmolecules were purified using poly-T oligo attachedmagnetic beads.
These were fragmented, reverse transcribed and further purified to separate blunted dscDNA for adaptor ligation. Library amplifica-
tion of 12 cycleswas used before purification with AMPure XP beads and quantificationwith theQubit dsDNAHS assay andQC using
the Aligent Bioanalyser. Sequencing was performed using the Illumina NextSeq 500/550 High-Output v2 kit on the NextSeq 550 plat-
form. 48 libraries were pooledin equimolar amounts and run across 3 High-Output Flow Cells.
For human samples, RNA samples were run on Bioanalyzer RNA 6000 nano chips to determine RIN values and sample concen-
trations were measured using Qubit RNA BR assay and 200 ng of starting material was used. RNaseq libraries were prepared using
the KAPAmRNAHyper prep kit with KAPA SeqCap Adapters. Fragmentation was done at 94C for 6 minutes and library amplification
of 12 cycles. Each library was quantified using Qubit dsDNA HS assay and average fragment size was determined using Bioanalyzer
DNA 1000 or DNA HS. Molarity of each library was calculated using the Qubit and BioA results and then normalized to 10 nM and
pooled, 24 libraries per pool. Each pool was then quantified using Qubit dsDNA HS assay and average fragment size determined
using Bioanalyzer DNA HS. Pooled library molarity was determined using Qubit and BioA. The libraries were sequenced on Illumina
HiSeq 2500 instrument. Dilute and denature was done according tomanufacturer’s instructions for ‘‘Dilute and Denature Libraries for
cBot Clustering,’’ Standard normalization method. Each 24-library pool was run on two lanes of a HiSeq High Output flow cell. All
human GSCs were processed at passage 3 from derivation.
Reduced Representation Bisulphite Sequencing (RRBS) Sample preparation
All samples were run in triplicate. DNA was extracted from cells using the QIAGEN DNeasy Blood and Tissue kit and sample con-
centration and quality was assessed using the Nanodrop. Samples were confirmed to have appropriate quality by ensuring 260/
280 values were 1.84-1.96 and 260/230 values of 1.93-2.21. RRBS was performed by the University of Edinburgh Clinical Research
Facility Genetics Core. 200ng of each sample was processedwith theOvation RRBSMethyl-Seq System 1- 16 (TecanGenomics Inc,Cell 184, 1–17.e1–e13, April 29, 2021 e10
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bisulfite-conversion reaction efficiency. DNAwas digested using themethylation-insensitive restriction enzyme,MspI, and fragments
were directly ligated to cohesive-ended adapters without the requirement for blunting or A-tailing. Bisulfite-conversion was
performed with the Epitect Fast Bisulfite Conversion Kit. Bisulfite- treated adaptor-ligated fragments were then amplified by PCR
(9 cycles) before purification using Agencourt RNAClean XP beads. RRBS libraries were quantified using the Qubit 2.0 fluorometer
and theQubit dsDNAHS assay andwere assessed for size and quality using the Agilent Bioanalyser with theDNAHSKit. Sequencing
was performed using the NextSeq 500/550 High-Output v2.5 Kit on the NextSeq 550 platform. Libraries were combined in three
equimolar pools of five and run on three high output flow cells, with 1% PhiX Control library
Whole genome sequencing (WGS) sample preparation
Genomic DNA (gDNA) was extracted from cells using the QIAGEN DNeasy Blood and Tissue kit and submitted to Edinburgh
Genomics for processing. Genomic DNA was quantified using Quant-iT Picogreen reagent, Lambda Standard DNA and a Molecular
Devices, Spectramax XPS Gemini plate reader. Quality of gDNA was evaluated using an AATI Fragment Analyzer and the Standard
Sensitivity Genomic DNA Analysis Kit. Genomic DNA samples > 1000ng and a quality score > 5 pass sample QC. Genomic DNA
samples were then pre-normalized to fall within 20-100ng/mL concentration range required for Illumina SeqLab TruSeq PCR Free
library preparation method using the Hamilton MicroLab STAR. Libraries were prepared using Illumina SeqLab specific TruSeq
PCR-Free High Throughput library preparation kits in conjunction with the Hamilton MicroLab STAR and Clarity LIMS X Edition
according to standard protocols. Genomic DNA was sheared to a 450bp mean insert size using a Covaris LE220 focused-ultraso-
nicator. Inserts were blunt ended, A-tailed, size selected and had TruSeq adapters ligated onto the ends. Insert size for each library
was evaluated using the Caliper GX Touch with a HT DNA 1k/12K/HI SENS LabChip and HT DNAHI SENS Reagent Kit to ensure that
mean fragment sizes fell between 300 bp and 800 bp. Library concentration was normalized to 1.5nM before being denatured for
clustering and sequencing at 300pM using a Hamilton MicroLab STAR with Genologics Clarity LIMS X (4.2) Edition. Libraries
were clustered onto a HiSeqX Flow cell v2.5 on cBot2s and the clustered flow cell was transferred to a HiSeqX for sequencing using
a HiSeqX Ten Reagent kit v2.5.
Bioinformatics Analysis
RNA-seq data processing and differential expression
RNA sequencing reads were trimmed with TrimGalore (version 0.5.0) and aligned to a reference genome using the pseudo aligner
Kallisto with default parameters (version 0.44.0) (Martin, 2011; Bray et al., 2016). For mouse and human samples mm10, and
hg38 were used respectively. Read counts were summarized via the R package Tximport (version 1.8.0) (Soneson et al., 2015)
and subsequent normalization was completed via DESeq2 (version 1.27.32) (Love et al., 2014). Reported normalized read counts,
unless otherwise stated, are as regularised-logarithm transformation (rlog) (Love et al., 2014). Differential expression was completed
using DESeq2with log2 fold change shrinkage (Love et al., 2014). Geneswith less than 1 read count across samples were pre-filtered.
Multiple testing was accounted for using the Benjamini-Hochberg procedure to calculate false discovery rates (FDRs) (Benjamini and
Hochberg, 1995). Principal component analysis (PCA) was completed on the top 500 genes with greatest variance across samples.
Where heatmaps of normalized expression are clustered this was completed usingWard’s method and Euclidean distance (Murtagh
and Legendre, 2014).
RNA-seq - Identifying genes specific to tumor derived mutants
Genes specific to NPE tumor derived (NPE-BL6-TD and NPE-IE), and NF1mutant samples (NF1, NP, NPE, NPE-BL6-TD, NPE-NSG-
TD, NPE-IE) were identified via the Distal binarization approach as previously described (Corces et al., 2018). In brief an intra-group
median and inter-quartile range (IQR) were calculated for each gene. For each gene, groups were then ranked by median expression
across replicates with BL6 WT samples as a baseline. For any gene where the median expression of a group was higher than 1.5
times the IQR than the group preceding it in rank, this gene was labeled specific to this sample group. All samples ranked higher
than this group based on gene expression were also labeled as gene specific. Genes were further filtered such that only specific
genes that were also differentially expressed (FDR < 0.05, LFC > 1) between relevant comparisons (NPE tumor derived
samples Vs. All others, and NF1 mutant samples Vs. All others) were retained (Love et al., 2014).
RNA-seq - Defining human subtypes
Genes with low expression (< 10 counts across all groups, with < 1 count per sample) and low variability of counts per million reads
(CPM) across GSC samples, as calculated by DESeq2, were filtered (SD < 5 across groups, and coefficient of variation < 0.25). A final
9291 geneswere subsequently used for downstream analysis. The NMFpackage in R (version 0.22.0) was used to perform the brunet
implementation of non-negative matrix factorisation using default parameters (Brunet et al., 2004; Gaujoux and Seoighe, 2010). The
highest cophenetic score was used as a criterion to obtain the optimal number of latent factors (Subtypes: S1 Non-MESImm, S2 ME-
SImm). Two distinct subtypes were consistently obtained when running NMF with different algorithms and returned the most stable
consensus clustering when compared with other rank numbers (Lee and Seung, 2001; Brunet et al., 2004; Pascual-Montano et al.,
2006). To extract gene features for each subtype the most specific genes were selected (S1 Non- MESImm: 589, S2 MESImm: 235
genes) with the Kim and Park method as implemented in the NMF package (Kim and Park, 2007). Subtype enrichment scorese11 Cell 184, 1–17.e1–e13, April 29, 2021
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subtype labels (S1 Non-MESImm, or S2 MESImm) were applied to each sample as the subtype with the highest enrichment score.
RNA-seq - Overrepresentation and gene set enrichment analysis
R packages clusterprofiler, (version 3.15.4) and ReactomePA (version 1.31.0) were used to find enriched gene sets for genes specific
to tumor derived mouse samples, and human subtypes S1 Non-MESImm, or S2 MESImm (Yu et al., 2012; Yu and He, 2016). Where
gene ratio is reported this is the number of genes in each pathway or GO term enriched in a gene list of interest (e.g., S1 or S2) divided
by the total number of genes in the gene list of interest. Gene set enrichment analysis (GSEA) was completed for differentially ex-
pressed gene sets via the Broad institute’s GSEA Preranked tool from the GSEA software package 3.0 (Subramanian et al.,
2005). For human samples the Gene ontology (GO) database for Biological process, Cellular component and Molecular process,
was utilized as a gene set database (Harris et al., 2004). For mouse samples an equivalent GO database was derived (Lai et al.,
2016a). Single sample gene set enrichment analysis (ssGSEA), with simplicity scores, was completed using a recent implementation
of the ssGSEA algorithm by Wang et al., with selected immune GO terms, and glioma subtype gene sets (Mesenchymal, Classical,
and Proneural) (Barbie et al., 2009; Wang et al., 2017).
Reduced representation bisulfite sequencing
Reads were trimmed with TrimGalore (version 0.5.0). NuGen diversity adaptors were removed with a Python script supplied by Nu-
Gen ‘‘trimRRBSdiversityAdaptCustomers.py’’ (version 1.11 https://github.com/nugentechnologies/NuMetRRBS) (Martin, 2011).
Reads were then aligned to the mm10 in silico bisulfite transformed genome with the bisulphite sequencing aligner Bismark (version
0.16.3 with Bowtie version 2.2.6 using parameters: -N 0 -L 20) (Krueger and Andrews, 2011). PCR duplicates were then removed
using a Python script from NuGen ‘‘nudup.py’’ (version 2.3 https://github.com/tecangenomics/nudup). Methylation estimation
was completed using the Bismark methylation extractor ignoring the first two bases of read 2 to minimize common methylation
call bias at these sites. Initial visualization with PCA was completed on the top 25% of CpGs with the highest variance of percentage
methylation. No batch effect was observed following PCA. Identification of differentially methylated loci (DMLs) was completed with
the R package DSS (version 2.36.0) inmultifactor mode to account for RRBSbatch (Park andWu, 2016). FDRwas used to account for
multiple testing (Benjamini and Hochberg, 1995). Differentially methylated regions (DMRs) were called by merging adjacent statisti-
cally significant DMLs within 50bp of one another, and filtering for DMRs with a minimum length of 50bp and with greater than 3
significant CpG sites. CpG island tracks were retrieved from the UCSC table browser service as a BED file (Karolchik et al.,
2004). Percentage methylation, DMRs, DMLs, and CpG island tracks were visualized using the IGV genome browser (Thorvaldsdóttir
et al., 2013). The annotation of DMRswas completed using the R package ChIPpeakAnno (version 3.22.0) – where DMRswere attrib-
uted to nearest gene promoter/transcription start site (TSS) (Zhu et al., 2010). TSS coordinates were defined as ± 2kb of sequence
surrounding the start of the first exon. Promoter rank plots were filtered to include DMRs overlapping promoter regions and associ-
ated hypomethylated immune genes were highlighted in blue (> 50%methylation loss, overlapping immune and interferon GO terms:
GO:0006955, GO:0034341, GO:0034340, GO:0035456, GO:0035455, andGO:0019882). Density heatmapswere produced using the
‘densityHeatmap’ function from the R package ComplexHeatmap (version 2.4.2), and clustering was completed using Euclidean dis-
tance and Ward’s method (Murtagh and Legendre, 2014; Gu, Eils and Schlesner, 2016).
Infinium MethylationEPIC BeadChip
Pre-processing and normalization from idat files to beta values was completed via the R package minfi (version 1.34.0) with com-
bined functional and Noob normalization (Triche et al., 2013; Fortin et al., 2014, 2017). Poor quality probes, and those that could
not be mapped to the hg38 genome, were filtered as previously described (Maksimovic et al., 2016; Zhou et al., 2017). Classification
of human EPIC array samples were completed via the online portal https://www.molecularneuropathology.org/mnp. IDH mutants
were removed prior to downstream methylation analysis (Capper et al., 2018). DMLs and DMRs were identified via the R Package
DMRCate (version 2.2.3) using limma (version 3.43.11) (Peters et al., 2015; Ritchie et al., 2015). Annotation of DMRs was completed
via the R package ChIPpeakAnno by assigning DMRs to nearest TSS (+/ 2kb) (Zhu et al., 2010). Density heatmaps were produced
using the ‘densityHeatmap’ function from the R package ‘ComplexHeatmap’, and clustering was completed using Euclidean dis-
tance with Ward’s method (Murtagh and Legendre, 2014; Gu et al., 2016).
Single-cell RNA-seq
Smart-seq2 single cell RNA-seq normalized counts (Transcripts per million, TPM) were downloaded from the Gene Expression
Omnibus (https://www.ncbi.nlm.nih.gov/geo/) (GEO accession: GSM3828672) for 7930 glioma cells, from 28 separate tumors (Neftel
et al., 2019). Contaminating cells (Macrophages, T Cells, and Oligodendrocytes) were filtered as previously described (Neftel et al.,
2019). Paediatric samples were then filtered prior to downstream analysis. PCAwas completed on the top 2000most variable genes.
As in the bulk RNA-Seq analysis ssGSEA was completed on each cell for glioma transcriptional subtypes, and immune GO terms.
Where subtype labels are applied to individual cells this was completed using ssGSEA - where an S2MESImm subtype was applied to
cells with aMESImm p value < 0.05, otherwise a S1Non-MESImm label was applied. Differential expression betweenMESImm andNon-
MESImm labeled cells was completed using the ‘findMarkers’ function from the R package scran (version 1.16.0) using default
parameters (Lun et al., 2016).Cell 184, 1–17.e1–e13, April 29, 2021 e12
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Whole genome sequencing (WGS) of BL6 WT, NPE and NPE-IE lines was completed using the best practises WGS paired cancer
normal pipeline bcbio (bcbio-nextgen version 1.2.3) (https://github.com/bcbio/bcbio-nextgen). Adaptors were trimmed with the
read trimmer Atropos (version 1.1.25) (Didion et al., 2017), a variant of Cutadapt, and aligned to the mm10 genome using the aligner
Bowtie2 (version 2.3.5.1) (Langmead and Salzberg, 2012). An additional human EGFRvIII contig was included to capture human
reads from the EGFRvIII transgene present in NPE and NPE-IE lines. PCR duplicates were marked with samblaster (version
0.1.25) (Faust and Hall, 2014), and GATK base quality score recalibration was completed on the aligned BAM files (gatk version
3.8) (DePristo et al., 2011). Single nucleotide variant (SNV) calling was completed using an ensemble-based approach using VarDict
(version 1.6), Strelka2 (version 2.9.10), and Mutect2 (gatk version 3.8) for somatic calling, and freebayes (version 1.1.0.46), GATK
HaplotypeCaller (gatk version 3.8), and Strelka2 (version 2.9.10) for germline calling (DePristo et al., 2011; Garrison and Marth,
2012; Cibulskis et al., 2013; Lai et al., 2016b; Kim et al., 2018). Germline calls were used to filter final somatic calls. Variants were
combined and included in the final call if present in 2 out of 3 variant callers (bcbio min_allele_fraction: 2). Variant calls were targeted
at exonic regions as defined by the R package TxDb.Mmusculus.UCSC.mm10.knownGene (version 3.4.4). Structural variants (SVs)
were called with Manta (version 1.6.0) (Chen et al., 2016). Structural variants that did not pass default Manta filters were removed.
Break-end (BND) calls for NPE and NPE-IE samples were either imprecise and without split read evidence or had less than 5 split
reads for the alternative allele, and hence were not considered for further analysis. Copy number variants (CNVs) were assessed
with CNVkit (version 0.9.6) (Talevich et al., 2016). To accommodate parameter flexibility, CNVKit was run outside of bcbio using
the ‘‘wgs’’ option, targeted at transcript regions as defined by the R package TxDb.Mmusculus.UCSC.mm10.knownGene. Absolute
copy number calls were completed with the ‘‘clonal’’ option to account for known high purity of cell line samples and copy number
regions were filtered using confidence interval filtering. SNV and SVs were annotated using the R packages VariantAnnotation
(version 1.34.0), TxDb.Mmusculus.UCSC.mm10.knownGene, and BSgenome.Mmusculus.UCSC.mm10.masked (version 1.3.99)
(Obenchain et al., 2014). Following annotation SNV calls were filtered again to remove those within noncoding regions, those that
were synonymous, as well as those with an allele frequency (AF) < 0.25. Final, filtered, SNV, SV, and CNV calls were overlapped
with known cancer driver genes as defined by the COSMIC gene census (https://cancer.sanger.ac.uk/census), converted to mouse
homologs via MGI batch query (http://www.informatics.jax.org/batch) (Sondka et al., 2018; Bult et al., 2019).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed on GraphPad or using R (version 4.0.0). Numerical data presented in charts is displayed as
mean ± SEM and analyzed using unpaired t tests unless otherwise stated in corresponding legends of the article. Statistical analysis
of survival data was performed on GraphPad using the Log Rank (Mantel-Cox) test. Significance is noted in figures or figure legends;
p values are denoted as follows: * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001, n.s. > 0.05.e13 Cell 184, 1–17.e1–e13, April 29, 2021
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Figure S1. Engineering GBM driver mutations in adult mouse neural stem cells to create GBM initiating cell lines, related to Figure 1 and
Table S1
(A) Immunoblots of EGFRvIII (left panel) and PDGFRa (right panel) overexpression in NSCs following transfection with the PB-Transposon plasmids.
(B) PCR genotyping of clonal Pten Knock-Out (KO) lines to confirm successful gene targeting.
(C) Immunoblot of Pten KO NSC lines confirms loss of PTEN protein expression.
(D) PCR genotyping of clonal Nf1 KO lines to confirm successful gene targeting.
(E) Immunoblot of Nf1 KO NSC lines confirms loss of NF1 protein expression.
(F) PCR genotyping of clonal Trp53 KO lines to confirm successful gene targeting.
(G) ICC analysis of Trp53 KO clones confirms loss of TRP53 expression, scale bar = 20mm.
(H) CRISPR KO of Pten, Nf1 and Trp53 in NSCs does not affect the expression of the common NSCmarkers Nestin or SOX2, or the ability of NSCs to respond to
differentiation cues (growth factor withdrawal and/or BMP addition), scale bar = 20mm.
(I) Orthotopic transplantation of NP cells into NOD-scid-gamma (NSG) mice provides a premalignant model (whole brain live imaging shown; top, GFP; bottom,
overlay of GFP and brightfield (BF), representative images of n = 5 mice).
(J) Immunoblots of the GBM driver mutations (NF1, PTEN and EGFRvIII) in engineered NPE-Mx (multiplex) NSCs.
(K) Top:Orthotopic transplantation of NPE-Mx cells leads to tumour formation in NSGmice (whole brain live imaging shown; top, GFP; bottom, overlay of GFP and
brightfield (BF)). Bottom: Survival curve of NSG mice orthotopically transplanted with NPE-Mx cells (n = 3 mice).
(L) Immunoblots of NF1, PTEN, and EGFR expression in NPE-Mx-TD (tumour-derived) polyclonal and clonal lines versus parental NSCs.
(M) Immunoblot of PDGFRa and PTEN in PPP NSCs.
(N) ICC confirming reduction of TRP53 expression in PPP cells versus parental NSCs (left panel) and quantification of Trp53-expressing cells by ICC (right panel;
student’s t-test *** p%0.001, error bars represent SEM), scale bar = 20mm.
(O) ICC of PPP mutant NSC lines for NSC markers (Sox2, Nestin) in self-renewing, EGF/FGF containing media and differentiation markers (GFAP, Tuj1) in dif-
ferentiation conditions (BMP or -EGF/-FGF), scale bar = 20mm.
(P) Bioluminescent IVIS imaging of PPP tumour progression in vivo in NSG and BL6 recipients. Number of days post-surgery is noted above each image.
(Q) Survival curve of NSG (n = 4) and BL6 (n = 15) mice transplanted with PPP cells
(R) Flow cytometric analysis of the NPE-BL6-TD cells confirms that no CD45+ cells are detectable in vitro as compared to unstained NPE-BL6-TD and bone
marrow-derived cells.
(S) Quantification of tumour incidence in NSG and BL6 mice transplanted with NPE, NPE-BL6-TD and NPE-IE cell lines. Numbers above bars denote actual
tumour occurrence in all transplants.
(T) Confluence analysis of NPE and NPE-IE cells indicates no significant difference in proliferation rates (p = 0.2888).
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Figure S2. Immune profiling of NPE andNPE-IE tumors reveals recapitulation of human disease and dynamic immune populations, related to
Figure 2
(A) Survival analysis of BL6 mice orthotopically injected with NPE (left), NPE-BL6-TD (center) or NPE-IE (right) cells and subjected to IP injection of anti-CD8 or
isotype matched control (IgG2b). NPE: n = 6 mice + ɑCD8, n = 5 mice + ɑIgG2b; p = 0.1002. NPE-BL6-TD: n = 6 mice + ɑCD8, n = 4 mice + ɑIgG2b; p = 0.1705.
NPE-IE: n = 12 + ɑCD8, n = 10 + ɑIgG2b; p = 0.0171).
(B) Example gating strategy to determine immune cell populations in normal and tumor-burdened whole brains.
(C) Quantification of the proportions of major immune cell populations in normal whole brains and tumor-burdened brains.
(D) Quantification of PD1+ TIM3+ CD4 and CD8 T cells in whole brains of non-transplanted BL6 mice versus those with tumors from transplanted NPE or NPE-IE
cells; n = 4 brains analyzed for each condition.
(E) Representative images of cell classification training used for macrophage quantification in NPE/NPE-IE fluorescent IHC images.
(F) Quantification of Iba1+ F4/80+macrophage populations as fraction of the total cell population (right). p values calculated with one-way ANOVA, n = 3 – 5 brains
from each condition analyzed.
ll
OPEN ACCESS Article
(legend on next page)
ll
OPEN ACCESSArticle
Figure S3. Immune evasive NPE-IE tumors possess a highly immunosuppressive TME, related to Figure 3
(A) & (B) Gating strategy to define myeloid (A) and lymphoid (B) populations in NPE and NPE-IE tumors.
(C) Representative histograms of PD-L1 expression onmicroglia andmacrophages in NPE-IE tumors (linked to Figure 3E). Control represents fully stained sample
minus anti-PD-L1 antibody.
(D) Representative histograms of CD206, CD86 and CD11c expression on macrophages from NPE and NPE-IE tumors. Data derived from 3 tumors randomly
down sampled for 50,000 live cells each. Control represents fully stained sample minus either anti-CD206, anti-CD86 or anti-CD11c antibodies.
(E) Flow cytometry quantification of the frequency of macrophages, M-MDSC and microglia positive for expression of PD-L1
(F) Flow cytometry quantification of the frequency of NK cells as a percentage of live cells.
(G) Flow cytometry quantification of the frequency of CD11b+ DCs as a percentage of live cells.
(H) Flow cytometry quantification of CD11b+ DCs positive for expression of PD-L1.
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Figure S4. Transcriptional and epigenetic reconfiguration occurs across mouse samples, with DNA hypomethylation occurring at key
immune-associated genes, related to Figures 4 and 5
(A) WGS copy number heatmap of log2 ratios of coverage for NPE and NPE-IE lines demonstrates genetic stability of mouse lines (gain of chrX evident as CNVs
were called against male reference).
(B) Principal Component Analysis (PCA) of RNA-seq data (top 500 most variable genes) for all cell line samples.
(C) Heatmap of Z-scaled normalized counts for genes specific to all cell lines engineeredwithNf1 loss ordered by log2 fold change (NF1 KO samples Vs. all others)
(top). Z-scaled normalized counts of specific genes shown in heatmap across all mutants (Red trend line indicates mean Z-scaled expression) (bottom).
(D) Pairwise comparisons of CpGmethylation changes between lines (excluding NP double mutant) as density scatterplots, and DMR bar plots – highlighting the
predominant hypomethylation within tumor derived samples.
(E) Rank plots of promoter DMRs (+/ 2kb TSS) displaying hypomethylation in NPE-NSG-TD lines versus NPE samples (DMRs with > 50% methylation loss,
overlapping genes within immune and interferon GO terms are highlighted in blue).
(F) Promoter DMRmethylation (%) across lines for Irf8,Nt5e andCd274, genes (top), and correlation with RNA-seq normalized counts (bottom) (SCC, and p value
reported).
(G) RNA-seq normalized counts of Nt5e across analyzed lines.
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Figure S5. Irf8 is responsive to IFNg and TAMs in NPE and PPP cells in vitro and is important for immune evasion, related to Figure 6
(A) Immunoblot analysis of Irf8 expression in NPE cells and subsequently tumor-derived lines with and without in vitro IFNg treatment (representative of n = 3
experiments).
(B) RT-qPCR analysis of Irf8 (left) and Ifih1 (right, confirms stimulation of IFN signaling) expression in untreated (UT) NPE, NPE-BL6-TD and NPE-IE cells versus
in vitro treatment with IFNa/b (a, b, respectively). Error bars represent SEM, RQ (relative quantification) relative to NPE untreated conditions.
(C) Schematic of Irf8-mCherry reporter design.
(D) Flow cytometric analysis of mCherry expression in NPE-Irf8-mCherry reporter lines ± IFNg treatment versus Parental NPE lines with adjunct histograms
showing population distributions.
(E) Gating strategy employed to isolate GFP+ tumor cells, CD45+CD3+ T cells and CD45hi/lo F4/80+ myeloid cells from NPE tumors in NSG or BL6 host mice.
Related to Figure 6E.
(legend continued on next page)
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(F) RT-qPCR analysis of selected target gene expression (H2-Ab1,H2-Q7 and Ifi47) in ‘immune naive’ NPE cells in vitro compared with cells derived directly from
NPE tumors in NSG and BL6 hosts. Each point represents technical duplicates of cells isolated from individual animals. Related to Figure 6E
(G) Heatmap illustrating expression levels of selected target gene expression (Irf8, H2-Q10, H2-Ab1, H2-Q7 and Ifi47) in untreated NPE cells versus those co-
cultured with NPE tumor-derived immune populations in vitro. Gene expression was determined by RT-qPCR and is displayed as normalized expression values
from technical duplicates of n = 3 biological replicates, related to Figure 6G.
(H) Heatmap illustrating expression levels of selected target gene expression (Irf8,H2-Q10 and H2-Ab1) in untreated PPP cells versus those co-cultured with NPE
tumor-derived immune populations in vitro. Gene expression was determined by RT-qPCR and is displayed as normalized expression values from technical
duplicates of n = 3 biological replicates.
(I) PCR genotyping of Irf8 locus in NPE-IE lines versus clonally derived NPE-IE Irf8 KO lines confirms successful gene targeting.
(J) Immunoblot of IRF8 expression in NPE-IE lines in the presence or absence of IFNg treatment in vitro.
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Figure S6. Non-negative matrix factorization (NMF) of bulk RNA-seq in patient-derived GSCs identifies two distinct subtypes, related to
Figure 7
(A) NMF of bulk RNA-seq highlights two predominant subgroups within patient-derived GBM GSCs. Consensus matrices for each NMF model across different
ranks, or number of considered meta-gene modules (Metagenes, Consensus cluster assignment, Silhouette score to assess cluster quality, -log10 p values for
Verhaak subtypes, and average connectivity across runs, are reported).
(B) Consensus matrices for different algorithms of rank 2 highlight stability across approaches (left). Cophenetic score computed for each number of considered
meta-genes (dotted line represents random data), highlight two subgroups as optimal (right).
(C) Heatmap of ssGSEA enrichment for MESImm signature across engineered mouse cell lines (-log10 p values (Red/Blue), and ssGSEA enrichment (red/yellow/
blue) are reported).
(D) PCA of publicly available scRNA-seq data of adult GBM cells (Neftel et al., 2019). Separation along PC2 is associated with IFN signaling genes (highlighted in
black), and mesenchymal subtype genes (CD44, CHI3L1, and VIM highlighted in red).
(E) scRNA-seq ssGSEA enrichment for select immune GO terms across adult GBM cells ordered by MESImm subtype p value.
(F) Heatmap of Z-score TPM scRNA-seq of adult GBM cells for IFN genes highlighted in Figure 7B (top), and IRF family members (bottom), ordered by MESImm
subtype p value. Differential expression between MESImm and Non-MESImm samples log2 fold change, percentile of effect size, and adjusted p values are
reported.
(G) Heatmap of Spearman’s rank correlation coefficient for gene sets from (S6F) with previously published subtypes (Non-MESImm, MESImm highlighted in red).
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Figure S7. Comparison of the MESImm subtype with published subtypes across single cell data—with hypomethylation evident in MESImm
samples, related to Figure 7
(A) Heatmap of -log10 ssGSEA p values for subtypes across single cell RNA-seq cohort (Neftel et al., 2019).
(B) Scatterplot of ssGSEA enrichment scores andmeanmethylation (beta-values) for each sample (red:MESImm, blue: Non-MESImm), with correlation coefficients
reported.
(C) Genome tracks of key DMRs for IRF1, CCL2, and IRF8 (red: MESImm, blue: Non- MESImm).
(D) Methylation (beta-value) at each CpG site within each corresponding DMR (trend lines denote LOESS curves).
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